python test.py         

  =============== Monkey patching loaders DONE
2024-12-15 21:52:44,690 - graphrag.config.read_dotenv - INFO - Loading pipeline .env file
⠋ GraphRAG Indexer 2024-12-15 21:52:44,693 - __main__ - INFO - Starting build_index with run_id=20241215-215244
Starting build_index with run_id=20241215-215244
⠋ GraphRAG Indexer 2024-12-15 21:52:44,697 - graphrag.index.create_pipeline_config - INFO - skipping workflows 
2024-12-15 21:52:44,697 - graphrag.index.run.run - INFO - Running pipeline
2024-12-15 21:52:44,697 - graphrag.storage.file_pipeline_storage - INFO - Creating file storage at /Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/plugins/dev/graphrag/python-lib/graphrag/test/output
2024-12-15 21:52:44,697 - graphrag.index.input.factory - INFO - loading input from root_dir=input
2024-12-15 21:52:44,697 - graphrag.index.input.factory - INFO - using file storage for input
⠋ GraphRAG Indexer 2024-12-15 21:52:44,698 - graphrag.storage.file_pipeline_storage - INFO - search /Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/plugins/dev/graphrag/python-lib/graphrag/test/input for files matching .*\.txt$
2024-12-15 21:52:44,699 - graphrag.index.input.text - INFO - found text files from input, found [('ctgov_fullcontent_1.txt', {})]
2024-12-15 21:52:44,700 - graphrag.index.input.text - INFO - Found 1 files, loading 1
2024-12-15 21:52:44,701 - graphrag.index.workflows.load - INFO - Workflow Run Order: ['create_base_text_units', 'create_final_documents', 'extract_graph', 'compute_communities', 'create_final_entities', 'create_final_relationships', 'create_final_communities', 'create_final_nodes', 'create_final_text_units', 'create_final_community_reports', 'generate_text_embeddings']
2024-12-15 21:52:44,701 - graphrag.index.run.run - INFO - Final # of rows loaded: 1
2024-12-15 21:52:44,759 - graphrag.index.run.workflow - INFO - dependencies for create_base_text_units: []
⠋ GraphRAG Indexer 
🚀 create_base_text_units
Empty DataFrame
Columns: []
Index: []
⠧ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
⠧ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
🚀 create_final_documents
                                                  id  human_readable_id                    title                                               text                                      text_unit_ids
0  3e483c6a024c09ea2f5d53d99bb05cc1da5c58382ecb1d...                  1  ctgov_fullcontent_1.txt  # NCTId\nNCT06273124\n# study_url\nhttps://www...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
⠇ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
⠏ GraphRAG Indexer 
 *************** index/graph/extractors/graph/graph_extractor.py: calling LLM
⠹ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
└── extract_graph
    └── Verb extract_graph ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━   0% -:--:-- 0:00:332024-12-15 21:53:21,005 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:53:21,005 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:53:21,006 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={}
2024-12-15 21:53:21,006 - DataikuChatLLM - INFO - DataikuChatLLM: Response text: ("entity"<|>TANDEM DIABETES CARE, INC.<|>ORGANIZATION<|>Tandem Diabetes Care, Inc. is the lead sponsor of a study on an investigational insulin infusion set for diabetes management.)
##
("entity"<|>JAEB CENTER FOR HEALTH RESEARCH<|>ORGANIZATION<|>Jaeb Center for Health Research is a collaborator in the insulin infusion set study.)
##
("entity"<|>ENDOCRINE RESEARCH SOLUTIONS<|>ORGANIZATION<|>Endocrine Research Solutions is a clinical site involved in recruiting for the study in Roswell, Georgia.)
##
("entity"<|>HENRY FORD HEALTH SYSTEM<|>ORGANIZATION<|>Henry Ford Health System is a clinical site that is indicated as not yet recruiting for the study in Detroit, Michigan.)
##
("entity"<|>HOAG MEMORIAL HOSPITAL PRESBYTERIAN<|>ORGANIZATION<|>Hoag Memorial Hospital Presbyterian is a clinical site currently recruiting for the study in Newport Beach, California.)
##
("entity"<|>INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS INSTITUTE<|>ORGANIZATION<|>International Diabetes Center is a clinical site that is not yet recruiting for the study in Minneapolis, Minnesota.)
##
("entity"<|>BARBARA DAVIS CENTER<|>ORGANIZATION<|>Barbara Davis Center is a clinical site that is not yet recruiting for the study in Aurora, Colorado.)
##
("entity"<|>NORTHWESTERN UNIVERSITY<|>ORGANIZATION<|>Northwestern University is a clinical site that is not yet recruiting for the study in Evanston, Illinois.)
##
("entity"<|>RAINIER CLINICAL RESEARCH CENTER<|>ORGANIZATION<|>Rainier Clinical Research Center is a clinical site that is not yet recruiting for the study in Renton, Washington.)
##
("entity"<|>TEXAS DIABETES AND ENDOCRINOLOGY<|>ORGANIZATION<|>Texas Diabetes and Endocrinology is a clinical site that is not yet recruiting for the study in Austin, Texas.)
##
("entity"<|>STANFORD UNIVERSITY<|>ORGANIZATION<|>Stanford University is a clinical site that is not yet recruiting for the study in Stanford, California.)
##
("entity"<|>UNIVERSITY OF WASHINGTON<|>ORGANIZATION<|>University of Washington is a clinical site that is not yet recruiting for the study in Seattle, Washington.)
##
("entity"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>ORGANIZATION<|>Icahn School of Medicine at Mt. Sinai is a clinical site that is not yet recruiting for the study in New York, New York.)
##
("entity"<|>MAYO CLINIC<|>ORGANIZATION<|>Mayo Clinic is a clinical site that is not yet recruiting for the study in Rochester, Minnesota.)
##
("entity"<|>ALAYNE LEHMAN<|>PERSON<|>Alayne Lehman is the study director from Capillary Biomedical overseeing the insulin infusion set study.)
##
("entity"<|>JOHN C REED<|>PERSON<|>John C Reed is a principal investigator at Endocrine Research Solutions involved in the insulin infusion set study.)
##
("entity"<|>DAVIDA KRUGER<|>PERSON<|>Davida Kruger is a principal investigator at Henry Ford Health System involved in the insulin infusion set study.)
##
("entity"<|>BRITTANY DENNIS<|>PERSON<|>Brittany Dennis is a contact person at Hoag Memorial Hospital Presbyterian for the insulin infusion set study.)
##
("entity"<|>RICHARD BERGENSTAL<|>PERSON<|>Richard Bergenstal is a principal investigator at the International Diabetes Center involved in the insulin infusion set study.)
##
("entity"<|>KATHRYN LEET<|>PERSON<|>Kathryn Leet is a contact at the International Diabetes Center for the insulin infusion set study.)
##
("entity"<|>SAMANTHA LANGE<|>PERSON<|>Samantha Lange is a contact person at Barbara Davis Center for the insulin infusion set study.)
##
("entity"<|>ERIN COBRY<|>PERSON<|>Erin Cobry is a principal investigator at Barbara Davis Center involved in the insulin infusion set study.)
##
("entity"<|>GRAZIA ALEPPO<|>PERSON<|>Grazia Aleppo is a principal investigator at Northwestern University involved in the insulin infusion set study.)
##
("entity"<|>WYATT LARSON<|>PERSON<|>Wyatt Larson is a contact at Rainier Clinical Research Center for the insulin infusion set study.)
##
("entity"<|>JEAN CHEN<|>PERSON<|>Jean Chen is a principal investigator at Texas Diabetes and Endocrinology involved in the insulin infusion set study.)
##
("entity"<|>EMMANUEL LOPEZ<|>PERSON<|>Emmanuel Lopez is a contact person at Texas Diabetes and Endocrinology for the insulin infusion set study.)
##
("entity"<|>TINA MITCHELL<|>PERSON<|>Tina Mitchell is a contact at Rainier Clinical Research Center for the insulin infusion set study.)
##
("entity"<|>RAYHAN LAL<|>PERSON<|>Rayhan Lal is a principal investigator at Stanford University involved in the insulin infusion set study.)
##
("entity"<|>DORI KHAKPOUR<|>PERSON<|>Dori Khakpour is a contact at University of Washington for the insulin infusion set study.)
##
("entity"<|>CAMILLA LEVISTER<|>PERSON<|>Camilla Levister is a principal investigator at Icahn School of Medicine involved in the insulin infusion set study.)
##
("entity"<|>DENISA TAMAREZ<|>PERSON<|>Denisa Tamarez is a contact person at Icahn School of Medicine for the insulin infusion set study.)
##
("relationship"<|>ALAYNE LEHMAN<|>TANDEM DIABETES CARE, INC.<|>Alayne Lehman is the study director for the insulin infusion set study sponsored by Tandem Diabetes Care, Inc.<|>8)
##
("relationship"<|>JOHN C REED<|>ENDOCRINE RESEARCH SOLUTIONS<|>John C Reed is a principal investigator associated with Endocrine Research Solutions for the insulin infusion set study.<|>8)
##
("relationship"<|>DAVIDA KRUGER<|>HENRY FORD HEALTH SYSTEM<|>Davida Kruger is a principal investigator associated with Henry Ford Health System for the insulin infusion set study.<|>8)
##
("relationship"<|>BRITTANY DENNIS<|>HOAG MEMORIAL HOSPITAL PRESBYTERIAN<|>Brittany Dennis serves as a contact person at Hoag Memorial Hospital Presbyterian for the insulin infusion set study.<|>7)
##
("relationship"<|>RICHARD BERGENSTAL<|>INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS INSTITUTE<|>Richard Bergenstal is a principal investigator at International Diabetes Center involved in the insulin infusion set study.<|>8)
##
("relationship"<|>KATHRYN LEET<|>INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS INSTITUTE<|>Kathryn Leet is a contact person at International Diabetes Center for the insulin infusion set study.<|>7)
##
("relationship"<|>SAMANTHA LANGE<|>BARBARA DAVIS CENTER<|>Samantha Lange is a contact person at Barbara Davis Center for the insulin infusion set study.<|>7)
##
("relationship"<|>ERIN COBRY<|>BARBARA DAVIS CENTER<|>Erin Cobry is a principal investigator at Barbara Davis Center involved in the insulin infusion set study.<|>8)
##
("relationship"<|>GRAZIA ALEPPO<|>NORTHWESTERN UNIVERSITY<|>Grazia Aleppo is a principal investigator at Northwestern University involved in the insulin infusion set study.<|>8)
##
("relationship"<|>WYATT LARSON<|>RAINIER CLINICAL RESEARCH CENTER<|>Wyatt Larson is a contact at Rainier Clinical Research Center for the insulin infusion set study.<|>7)
##
("relationship"<|>JEAN CHEN<|>TEXAS DIABETES AND ENDOCRINOLOGY<|>Jean Chen is a principal investigator at Texas Diabetes and Endocrinology involved in the insulin infusion set study.<|>8)
##
("relationship"<|>EMMANUEL LOPEZ<|>TEXAS DIABETES AND ENDOCRINOLOGY<|>Emmanuel Lopez is a contact person at Texas Diabetes and Endocrinology for the insulin infusion set study.<|>7)
##
("relationship"<|>RAYHAN LAL<|>STANFORD UNIVERSITY<|>Rayhan Lal is a principal investigator at Stanford University involved in the insulin infusion set study.<|>8)
##
("relationship"<|>DORI KHAKPOUR<|>UNIVERSITY OF WASHINGTON<|>Dori Khakpour is a contact person at University of Washington for the insulin infusion set study.<|>7)
##
("relationship"<|>CAMILLA LEVISTER<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>Camilla Levister is a principal investigator at Icahn School of Medicine involved in the insulin infusion set study.<|>8)
##
("relationship"<|>DENISA TAMAREZ<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>Denisa Tamarez is a contact person at Icahn School of Medicine for the insulin infusion set study.<|>7)
 *************** index/graph/extractors/graph/graph_extractor.py: for i in range, calling LLM
⠼ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
└── extract_graph
    └── Verb extract_graph ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━   0% -:--:-- 0:00:342024-12-15 21:53:21,936 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:53:21,937 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:53:21,937 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={'name': 'extract-continuation-0', 'history': [{'content': '\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity\'s attributes and activities\nFormat each entity as ("entity"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as ("relationship"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis\'s Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n("entity"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n("entity"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n("entity"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis\'s money supply)\n##\n("relationship"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal\'s (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation\'s debut on the public markets isn\'t indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n("entity"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n("entity"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n("relationship"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad\'s capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia\'s capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia\'s Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n("entity"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n("entity"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n("entity"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n("entity"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n("entity"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n("entity"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n("entity"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia\'s Alhamia Prison)\n##\n("entity"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n("entity"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n("entity"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n("relationship"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n("relationship"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: # NCTId\nNCT06273124\n# study_url\nhttps://www.clinicaltrials.gov/study/NCT06273124\n# BriefTitle\nInvestigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes\n# OfficialTitle\nOpen, Single Arm, Prospective, Multicenter Study of an Investigational Extended Wear Insulin Infusion Set During Home Use in People With Type 1 Diabetes\n# OverallStatus\nRECRUITING\n# StartDate\n2024-03-07\n# PrimaryCompletionDate\n2025-01-15\n# CompletionDate\n2025-01-15\n# LeadSponsorName\nTandem Diabetes Care, Inc.\n# LeadSponsorClass\nINDUSTRY\n# BriefSummary\nThe purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS).\n\nParticipants will be asked to:\n\n1. Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods\n2. Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL for one hour\n# StudyType\nINTERVENTIONAL\n# Phase\n[\'NA\']\n# DesignAllocation\nNA\n# DesignInterventionModel\nSINGLE_GROUP\n# DesignPrimaryPurpose\nTREATMENT\n# DesignMasking\nNONE\n# EnrollmentCount\n260\n# EnrollmentType\nESTIMATED\n# HealthyVolunteers\nFalse\n# Sex\nALL\n# StdAge\n[\'ADULT\', \'OLDER_ADULT\']\n# collaborators\nJaeb Center for Health Research (OTHER)\n# officials\nAlayne Lehman, RN, MS - Capillary Biomedical (STUDY_DIRECTOR)\n# clinical_site_contact\nEndocrine Research Solutions (RECRUITING), Roswell, Georgia, 30076, United States - John C Reed, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Jessica Tapia (CONTACT), 678-878-4750, jtapia.ers@gmail.com | Henry Ford Health System (NOT_YET_RECRUITING), Detroit, Michigan, 48202, United States - Davida Kruger, NP (PRINCIPAL_INVESTIGATOR), NA, NA | Davida Kruger (CONTACT), 313-916-3906, dkruger1@hfhs.org | Hoag Memorial Hospital Presbyterian (RECRUITING), Newport Beach, California, 92663, United States - Brittany Dennis (CONTACT), 949-764-6896, brittany.dennis@hoag.org | David Ahn, MD (PRINCIPAL_INVESTIGATOR), NA, NA | International Diabetes Center - HealthPartners Institute (NOT_YET_RECRUITING), Minneapolis, Minnesota, 55416, United States - Richard Bergenstal, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Kathryn Leet, RD,LD, CDCES (CONTACT), 952-993-9793, kathryn.leet@parknicollet.com | Barbara Davis Center (NOT_YET_RECRUITING), Aurora, Colorado, 80045, United States - Samantha Lange (CONTACT), 303-724-7514, samantha.lange@cuanschutz.edu | Erin Cobry, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Northwestern University (NOT_YET_RECRUITING), Evanston, Illinois, 60208, United States - Grazia Aleppo, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Grazia Aleppo (CONTACT), 312-926-5431, aleppo@northwestern.edu | Rocky Mountain Clinical Research (NOT_YET_RECRUITING), Idaho Falls, Idaho, 83404, United States - Wyatt Larson (CONTACT), 208-525-3736, Wyatt.larson@idahomed.com | David Liljenquist, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Texas Diabetes and Endocrinology (NOT_YET_RECRUITING), Austin, Texas, 78731, United States - Jean Chen, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Emmanuel Lopez (CONTACT), 512-334-3505, elopez@texasdiabetes.com | Rainier Clinical Research Center (NOT_YET_RECRUITING), Renton, Washington, 98057, United States - Tina Mitchell (CONTACT), 425-251-1720, TMitchell@rainier-research.com | Frances Broyles, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Stanford University (NOT_YET_RECRUITING), Stanford, California, 94305, United States - Rayhan Lal (CONTACT), 925-727-1317, inforay@stanford.edu | Rayhan Lal, MD (PRINCIPAL_INVESTIGATOR), NA, NA | University of Washington (NOT_YET_RECRUITING), Seattle, Washington, 98109, United States - Dori Khakpour (CONTACT), 206-945-4965, dorik@uw.edu | Irl Hirsch, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Icahn School of Medicine at Mt. Sinai (NOT_YET_RECRUITING), New York, New York, 10029, United States - Camilla Levister, MS, ANCP-C (PRINCIPAL_INVESTIGATOR), NA, NA | Denisa Tamarez (CONTACT), 212-241-9089, denisa.tamarez@mssm.edu | Mayo Clinic (NOT_YET_RECRUITING), Rochester, Minnesota,\n######################\nOutput:', 'role': 'user'}, ChatCompletionMessage(content='("entity"<|>TANDEM DIABETES CARE, INC.<|>ORGANIZATION<|>Tandem Diabetes Care, Inc. is the lead sponsor of a study on an investigational insulin infusion set for diabetes management.)\n##\n("entity"<|>JAEB CENTER FOR HEALTH RESEARCH<|>ORGANIZATION<|>Jaeb Center for Health Research is a collaborator in the insulin infusion set study.)\n##\n("entity"<|>ENDOCRINE RESEARCH SOLUTIONS<|>ORGANIZATION<|>Endocrine Research Solutions is a clinical site involved in recruiting for the study in Roswell, Georgia.)\n##\n("entity"<|>HENRY FORD HEALTH SYSTEM<|>ORGANIZATION<|>Henry Ford Health System is a clinical site that is indicated as not yet recruiting for the study in Detroit, Michigan.)\n##\n("entity"<|>HOAG MEMORIAL HOSPITAL PRESBYTERIAN<|>ORGANIZATION<|>Hoag Memorial Hospital Presbyterian is a clinical site currently recruiting for the study in Newport Beach, California.)\n##\n("entity"<|>INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS INSTITUTE<|>ORGANIZATION<|>International Diabetes Center is a clinical site that is not yet recruiting for the study in Minneapolis, Minnesota.)\n##\n("entity"<|>BARBARA DAVIS CENTER<|>ORGANIZATION<|>Barbara Davis Center is a clinical site that is not yet recruiting for the study in Aurora, Colorado.)\n##\n("entity"<|>NORTHWESTERN UNIVERSITY<|>ORGANIZATION<|>Northwestern University is a clinical site that is not yet recruiting for the study in Evanston, Illinois.)\n##\n("entity"<|>RAINIER CLINICAL RESEARCH CENTER<|>ORGANIZATION<|>Rainier Clinical Research Center is a clinical site that is not yet recruiting for the study in Renton, Washington.)\n##\n("entity"<|>TEXAS DIABETES AND ENDOCRINOLOGY<|>ORGANIZATION<|>Texas Diabetes and Endocrinology is a clinical site that is not yet recruiting for the study in Austin, Texas.)\n##\n("entity"<|>STANFORD UNIVERSITY<|>ORGANIZATION<|>Stanford University is a clinical site that is not yet recruiting for the study in Stanford, California.)\n##\n("entity"<|>UNIVERSITY OF WASHINGTON<|>ORGANIZATION<|>University of Washington is a clinical site that is not yet recruiting for the study in Seattle, Washington.)\n##\n("entity"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>ORGANIZATION<|>Icahn School of Medicine at Mt. Sinai is a clinical site that is not yet recruiting for the study in New York, New York.)\n##\n("entity"<|>MAYO CLINIC<|>ORGANIZATION<|>Mayo Clinic is a clinical site that is not yet recruiting for the study in Rochester, Minnesota.)\n##\n("entity"<|>ALAYNE LEHMAN<|>PERSON<|>Alayne Lehman is the study director from Capillary Biomedical overseeing the insulin infusion set study.)\n##\n("entity"<|>JOHN C REED<|>PERSON<|>John C Reed is a principal investigator at Endocrine Research Solutions involved in the insulin infusion set study.)\n##\n("entity"<|>DAVIDA KRUGER<|>PERSON<|>Davida Kruger is a principal investigator at Henry Ford Health System involved in the insulin infusion set study.)\n##\n("entity"<|>BRITTANY DENNIS<|>PERSON<|>Brittany Dennis is a contact person at Hoag Memorial Hospital Presbyterian for the insulin infusion set study.)\n##\n("entity"<|>RICHARD BERGENSTAL<|>PERSON<|>Richard Bergenstal is a principal investigator at the International Diabetes Center involved in the insulin infusion set study.)\n##\n("entity"<|>KATHRYN LEET<|>PERSON<|>Kathryn Leet is a contact at the International Diabetes Center for the insulin infusion set study.)\n##\n("entity"<|>SAMANTHA LANGE<|>PERSON<|>Samantha Lange is a contact person at Barbara Davis Center for the insulin infusion set study.)\n##\n("entity"<|>ERIN COBRY<|>PERSON<|>Erin Cobry is a principal investigator at Barbara Davis Center involved in the insulin infusion set study.)\n##\n("entity"<|>GRAZIA ALEPPO<|>PERSON<|>Grazia Aleppo is a principal investigator at Northwestern University involved in the insulin infusion set study.)\n##\n("entity"<|>WYATT LARSON<|>PERSON<|>Wyatt Larson is a contact at Rainier Clinical Research Center for the insulin infusion set study.)\n##\n("entity"<|>JEAN CHEN<|>PERSON<|>Jean Chen is a principal investigator at Texas Diabetes and Endocrinology involved in the insulin infusion set study.)\n##\n("entity"<|>EMMANUEL LOPEZ<|>PERSON<|>Emmanuel Lopez is a contact person at Texas Diabetes and Endocrinology for the insulin infusion set study.)\n##\n("entity"<|>TINA MITCHELL<|>PERSON<|>Tina Mitchell is a contact at Rainier Clinical Research Center for the insulin infusion set study.)\n##\n("entity"<|>RAYHAN LAL<|>PERSON<|>Rayhan Lal is a principal investigator at Stanford University involved in the insulin infusion set study.)\n##\n("entity"<|>DORI KHAKPOUR<|>PERSON<|>Dori Khakpour is a contact at University of Washington for the insulin infusion set study.)\n##\n("entity"<|>CAMILLA LEVISTER<|>PERSON<|>Camilla Levister is a principal investigator at Icahn School of Medicine involved in the insulin infusion set study.)\n##\n("entity"<|>DENISA TAMAREZ<|>PERSON<|>Denisa Tamarez is a contact person at Icahn School of Medicine for the insulin infusion set study.)\n##\n("relationship"<|>ALAYNE LEHMAN<|>TANDEM DIABETES CARE, INC.<|>Alayne Lehman is the study director for the insulin infusion set study sponsored by Tandem Diabetes Care, Inc.<|>8)\n##\n("relationship"<|>JOHN C REED<|>ENDOCRINE RESEARCH SOLUTIONS<|>John C Reed is a principal investigator associated with Endocrine Research Solutions for the insulin infusion set study.<|>8)\n##\n("relationship"<|>DAVIDA KRUGER<|>HENRY FORD HEALTH SYSTEM<|>Davida Kruger is a principal investigator associated with Henry Ford Health System for the insulin infusion set study.<|>8)\n##\n("relationship"<|>BRITTANY DENNIS<|>HOAG MEMORIAL HOSPITAL PRESBYTERIAN<|>Brittany Dennis serves as a contact person at Hoag Memorial Hospital Presbyterian for the insulin infusion set study.<|>7)\n##\n("relationship"<|>RICHARD BERGENSTAL<|>INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS INSTITUTE<|>Richard Bergenstal is a principal investigator at International Diabetes Center involved in the insulin infusion set study.<|>8)\n##\n("relationship"<|>KATHRYN LEET<|>INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS INSTITUTE<|>Kathryn Leet is a contact person at International Diabetes Center for the insulin infusion set study.<|>7)\n##\n("relationship"<|>SAMANTHA LANGE<|>BARBARA DAVIS CENTER<|>Samantha Lange is a contact person at Barbara Davis Center for the insulin infusion set study.<|>7)\n##\n("relationship"<|>ERIN COBRY<|>BARBARA DAVIS CENTER<|>Erin Cobry is a principal investigator at Barbara Davis Center involved in the insulin infusion set study.<|>8)\n##\n("relationship"<|>GRAZIA ALEPPO<|>NORTHWESTERN UNIVERSITY<|>Grazia Aleppo is a principal investigator at Northwestern University involved in the insulin infusion set study.<|>8)\n##\n("relationship"<|>WYATT LARSON<|>RAINIER CLINICAL RESEARCH CENTER<|>Wyatt Larson is a contact at Rainier Clinical Research Center for the insulin infusion set study.<|>7)\n##\n("relationship"<|>JEAN CHEN<|>TEXAS DIABETES AND ENDOCRINOLOGY<|>Jean Chen is a principal investigator at Texas Diabetes and Endocrinology involved in the insulin infusion set study.<|>8)\n##\n("relationship"<|>EMMANUEL LOPEZ<|>TEXAS DIABETES AND ENDOCRINOLOGY<|>Emmanuel Lopez is a contact person at Texas Diabetes and Endocrinology for the insulin infusion set study.<|>7)\n##\n("relationship"<|>RAYHAN LAL<|>STANFORD UNIVERSITY<|>Rayhan Lal is a principal investigator at Stanford University involved in the insulin infusion set study.<|>8)\n##\n("relationship"<|>DORI KHAKPOUR<|>UNIVERSITY OF WASHINGTON<|>Dori Khakpour is a contact person at University of Washington for the insulin infusion set study.<|>7)\n##\n("relationship"<|>CAMILLA LEVISTER<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>Camilla Levister is a principal investigator at Icahn School of Medicine involved in the insulin infusion set study.<|>8)\n##\n("relationship"<|>DENISA TAMAREZ<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>Denisa Tamarez is a contact person at Icahn School of Medicine for the insulin infusion set study.<|>7)\n##\n("relationship"<|>MAYO CLINIC<|>MAYO CLINIC<|>Mayo Clinic is a clinical site involved in the insulin infusion set study.<|>7)\n<|COMPLETE|>', refusal=None, role='assistant', audio=None, function_call=None, tool_calls=[], name=None)]}
2024-12-15 21:53:21,940 - DataikuChatLLM - INFO - DataikuChatLLM: Response text: Sure, please provide the details of the entities and relationships you would like me to extract or include, and I'll format them accordingly.
2024-12-15 21:53:21,940 - DataikuChatLLM - INFO - DataikuChatLLM: history=[{'content': '\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity\'s attributes and activities\nFormat each entity as ("entity"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as ("relationship"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis\'s Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n("entity"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n("entity"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n("entity"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis\'s money supply)\n##\n("relationship"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal\'s (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation\'s debut on the public markets isn\'t indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n("entity"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n("entity"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n("relationship"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad\'s capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia\'s capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia\'s Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n("entity"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n("entity"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n("entity"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n("entity"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n("entity"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n("entity"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n("entity"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia\'s Alhamia Prison)\n##\n("entity"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n("entity"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n("entity"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n("relationship"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n("relationship"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: # NCTId\nNCT06273124\n# study_url\nhttps://www.clinicaltrials.gov/study/NCT06273124\n# BriefTitle\nInvestigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes\n# OfficialTitle\nOpen, Single Arm, Prospective, Multicenter Study of an Investigational Extended Wear Insulin Infusion Set During Home Use in People With Type 1 Diabetes\n# OverallStatus\nRECRUITING\n# StartDate\n2024-03-07\n# PrimaryCompletionDate\n2025-01-15\n# CompletionDate\n2025-01-15\n# LeadSponsorName\nTandem Diabetes Care, Inc.\n# LeadSponsorClass\nINDUSTRY\n# BriefSummary\nThe purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS).\n\nParticipants will be asked to:\n\n1. Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods\n2. Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL for one hour\n# StudyType\nINTERVENTIONAL\n# Phase\n[\'NA\']\n# DesignAllocation\nNA\n# DesignInterventionModel\nSINGLE_GROUP\n# DesignPrimaryPurpose\nTREATMENT\n# DesignMasking\nNONE\n# EnrollmentCount\n260\n# EnrollmentType\nESTIMATED\n# HealthyVolunteers\nFalse\n# Sex\nALL\n# StdAge\n[\'ADULT\', \'OLDER_ADULT\']\n# collaborators\nJaeb Center for Health Research (OTHER)\n# officials\nAlayne Lehman, RN, MS - Capillary Biomedical (STUDY_DIRECTOR)\n# clinical_site_contact\nEndocrine Research Solutions (RECRUITING), Roswell, Georgia, 30076, United States - John C Reed, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Jessica Tapia (CONTACT), 678-878-4750, jtapia.ers@gmail.com | Henry Ford Health System (NOT_YET_RECRUITING), Detroit, Michigan, 48202, United States - Davida Kruger, NP (PRINCIPAL_INVESTIGATOR), NA, NA | Davida Kruger (CONTACT), 313-916-3906, dkruger1@hfhs.org | Hoag Memorial Hospital Presbyterian (RECRUITING), Newport Beach, California, 92663, United States - Brittany Dennis (CONTACT), 949-764-6896, brittany.dennis@hoag.org | David Ahn, MD (PRINCIPAL_INVESTIGATOR), NA, NA | International Diabetes Center - HealthPartners Institute (NOT_YET_RECRUITING), Minneapolis, Minnesota, 55416, United States - Richard Bergenstal, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Kathryn Leet, RD,LD, CDCES (CONTACT), 952-993-9793, kathryn.leet@parknicollet.com | Barbara Davis Center (NOT_YET_RECRUITING), Aurora, Colorado, 80045, United States - Samantha Lange (CONTACT), 303-724-7514, samantha.lange@cuanschutz.edu | Erin Cobry, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Northwestern University (NOT_YET_RECRUITING), Evanston, Illinois, 60208, United States - Grazia Aleppo, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Grazia Aleppo (CONTACT), 312-926-5431, aleppo@northwestern.edu | Rocky Mountain Clinical Research (NOT_YET_RECRUITING), Idaho Falls, Idaho, 83404, United States - Wyatt Larson (CONTACT), 208-525-3736, Wyatt.larson@idahomed.com | David Liljenquist, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Texas Diabetes and Endocrinology (NOT_YET_RECRUITING), Austin, Texas, 78731, United States - Jean Chen, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Emmanuel Lopez (CONTACT), 512-334-3505, elopez@texasdiabetes.com | Rainier Clinical Research Center (NOT_YET_RECRUITING), Renton, Washington, 98057, United States - Tina Mitchell (CONTACT), 425-251-1720, TMitchell@rainier-research.com | Frances Broyles, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Stanford University (NOT_YET_RECRUITING), Stanford, California, 94305, United States - Rayhan Lal (CONTACT), 925-727-1317, inforay@stanford.edu | Rayhan Lal, MD (PRINCIPAL_INVESTIGATOR), NA, NA | University of Washington (NOT_YET_RECRUITING), Seattle, Washington, 98109, United States - Dori Khakpour (CONTACT), 206-945-4965, dorik@uw.edu | Irl Hirsch, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Icahn School of Medicine at Mt. Sinai (NOT_YET_RECRUITING), New York, New York, 10029, United States - Camilla Levister, MS, ANCP-C (PRINCIPAL_INVESTIGATOR), NA, NA | Denisa Tamarez (CONTACT), 212-241-9089, denisa.tamarez@mssm.edu | Mayo Clinic (NOT_YET_RECRUITING), Rochester, Minnesota,\n######################\nOutput:', 'role': 'user'}, ChatCompletionMessage(content='("entity"<|>TANDEM DIABETES CARE, INC.<|>ORGANIZATION<|>Tandem Diabetes Care, Inc. is the lead sponsor of a study on an investigational insulin infusion set for diabetes management.)\n##\n("entity"<|>JAEB CENTER FOR HEALTH RESEARCH<|>ORGANIZATION<|>Jaeb Center for Health Research is a collaborator in the insulin infusion set study.)\n##\n("entity"<|>ENDOCRINE RESEARCH SOLUTIONS<|>ORGANIZATION<|>Endocrine Research Solutions is a clinical site involved in recruiting for the study in Roswell, Georgia.)\n##\n("entity"<|>HENRY FORD HEALTH SYSTEM<|>ORGANIZATION<|>Henry Ford Health System is a clinical site that is indicated as not yet recruiting for the study in Detroit, Michigan.)\n##\n("entity"<|>HOAG MEMORIAL HOSPITAL PRESBYTERIAN<|>ORGANIZATION<|>Hoag Memorial Hospital Presbyterian is a clinical site currently recruiting for the study in Newport Beach, California.)\n##\n("entity"<|>INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS INSTITUTE<|>ORGANIZATION<|>International Diabetes Center is a clinical site that is not yet recruiting for the study in Minneapolis, Minnesota.)\n##\n("entity"<|>BARBARA DAVIS CENTER<|>ORGANIZATION<|>Barbara Davis Center is a clinical site that is not yet recruiting for the study in Aurora, Colorado.)\n##\n("entity"<|>NORTHWESTERN UNIVERSITY<|>ORGANIZATION<|>Northwestern University is a clinical site that is not yet recruiting for the study in Evanston, Illinois.)\n##\n("entity"<|>RAINIER CLINICAL RESEARCH CENTER<|>ORGANIZATION<|>Rainier Clinical Research Center is a clinical site that is not yet recruiting for the study in Renton, Washington.)\n##\n("entity"<|>TEXAS DIABETES AND ENDOCRINOLOGY<|>ORGANIZATION<|>Texas Diabetes and Endocrinology is a clinical site that is not yet recruiting for the study in Austin, Texas.)\n##\n("entity"<|>STANFORD UNIVERSITY<|>ORGANIZATION<|>Stanford University is a clinical site that is not yet recruiting for the study in Stanford, California.)\n##\n("entity"<|>UNIVERSITY OF WASHINGTON<|>ORGANIZATION<|>University of Washington is a clinical site that is not yet recruiting for the study in Seattle, Washington.)\n##\n("entity"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>ORGANIZATION<|>Icahn School of Medicine at Mt. Sinai is a clinical site that is not yet recruiting for the study in New York, New York.)\n##\n("entity"<|>MAYO CLINIC<|>ORGANIZATION<|>Mayo Clinic is a clinical site that is not yet recruiting for the study in Rochester, Minnesota.)\n##\n("entity"<|>ALAYNE LEHMAN<|>PERSON<|>Alayne Lehman is the study director from Capillary Biomedical overseeing the insulin infusion set study.)\n##\n("entity"<|>JOHN C REED<|>PERSON<|>John C Reed is a principal investigator at Endocrine Research Solutions involved in the insulin infusion set study.)\n##\n("entity"<|>DAVIDA KRUGER<|>PERSON<|>Davida Kruger is a principal investigator at Henry Ford Health System involved in the insulin infusion set study.)\n##\n("entity"<|>BRITTANY DENNIS<|>PERSON<|>Brittany Dennis is a contact person at Hoag Memorial Hospital Presbyterian for the insulin infusion set study.)\n##\n("entity"<|>RICHARD BERGENSTAL<|>PERSON<|>Richard Bergenstal is a principal investigator at the International Diabetes Center involved in the insulin infusion set study.)\n##\n("entity"<|>KATHRYN LEET<|>PERSON<|>Kathryn Leet is a contact at the International Diabetes Center for the insulin infusion set study.)\n##\n("entity"<|>SAMANTHA LANGE<|>PERSON<|>Samantha Lange is a contact person at Barbara Davis Center for the insulin infusion set study.)\n##\n("entity"<|>ERIN COBRY<|>PERSON<|>Erin Cobry is a principal investigator at Barbara Davis Center involved in the insulin infusion set study.)\n##\n("entity"<|>GRAZIA ALEPPO<|>PERSON<|>Grazia Aleppo is a principal investigator at Northwestern University involved in the insulin infusion set study.)\n##\n("entity"<|>WYATT LARSON<|>PERSON<|>Wyatt Larson is a contact at Rainier Clinical Research Center for the insulin infusion set study.)\n##\n("entity"<|>JEAN CHEN<|>PERSON<|>Jean Chen is a principal investigator at Texas Diabetes and Endocrinology involved in the insulin infusion set study.)\n##\n("entity"<|>EMMANUEL LOPEZ<|>PERSON<|>Emmanuel Lopez is a contact person at Texas Diabetes and Endocrinology for the insulin infusion set study.)\n##\n("entity"<|>TINA MITCHELL<|>PERSON<|>Tina Mitchell is a contact at Rainier Clinical Research Center for the insulin infusion set study.)\n##\n("entity"<|>RAYHAN LAL<|>PERSON<|>Rayhan Lal is a principal investigator at Stanford University involved in the insulin infusion set study.)\n##\n("entity"<|>DORI KHAKPOUR<|>PERSON<|>Dori Khakpour is a contact at University of Washington for the insulin infusion set study.)\n##\n("entity"<|>CAMILLA LEVISTER<|>PERSON<|>Camilla Levister is a principal investigator at Icahn School of Medicine involved in the insulin infusion set study.)\n##\n("entity"<|>DENISA TAMAREZ<|>PERSON<|>Denisa Tamarez is a contact person at Icahn School of Medicine for the insulin infusion set study.)\n##\n("relationship"<|>ALAYNE LEHMAN<|>TANDEM DIABETES CARE, INC.<|>Alayne Lehman is the study director for the insulin infusion set study sponsored by Tandem Diabetes Care, Inc.<|>8)\n##\n("relationship"<|>JOHN C REED<|>ENDOCRINE RESEARCH SOLUTIONS<|>John C Reed is a principal investigator associated with Endocrine Research Solutions for the insulin infusion set study.<|>8)\n##\n("relationship"<|>DAVIDA KRUGER<|>HENRY FORD HEALTH SYSTEM<|>Davida Kruger is a principal investigator associated with Henry Ford Health System for the insulin infusion set study.<|>8)\n##\n("relationship"<|>BRITTANY DENNIS<|>HOAG MEMORIAL HOSPITAL PRESBYTERIAN<|>Brittany Dennis serves as a contact person at Hoag Memorial Hospital Presbyterian for the insulin infusion set study.<|>7)\n##\n("relationship"<|>RICHARD BERGENSTAL<|>INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS INSTITUTE<|>Richard Bergenstal is a principal investigator at International Diabetes Center involved in the insulin infusion set study.<|>8)\n##\n("relationship"<|>KATHRYN LEET<|>INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS INSTITUTE<|>Kathryn Leet is a contact person at International Diabetes Center for the insulin infusion set study.<|>7)\n##\n("relationship"<|>SAMANTHA LANGE<|>BARBARA DAVIS CENTER<|>Samantha Lange is a contact person at Barbara Davis Center for the insulin infusion set study.<|>7)\n##\n("relationship"<|>ERIN COBRY<|>BARBARA DAVIS CENTER<|>Erin Cobry is a principal investigator at Barbara Davis Center involved in the insulin infusion set study.<|>8)\n##\n("relationship"<|>GRAZIA ALEPPO<|>NORTHWESTERN UNIVERSITY<|>Grazia Aleppo is a principal investigator at Northwestern University involved in the insulin infusion set study.<|>8)\n##\n("relationship"<|>WYATT LARSON<|>RAINIER CLINICAL RESEARCH CENTER<|>Wyatt Larson is a contact at Rainier Clinical Research Center for the insulin infusion set study.<|>7)\n##\n("relationship"<|>JEAN CHEN<|>TEXAS DIABETES AND ENDOCRINOLOGY<|>Jean Chen is a principal investigator at Texas Diabetes and Endocrinology involved in the insulin infusion set study.<|>8)\n##\n("relationship"<|>EMMANUEL LOPEZ<|>TEXAS DIABETES AND ENDOCRINOLOGY<|>Emmanuel Lopez is a contact person at Texas Diabetes and Endocrinology for the insulin infusion set study.<|>7)\n##\n("relationship"<|>RAYHAN LAL<|>STANFORD UNIVERSITY<|>Rayhan Lal is a principal investigator at Stanford University involved in the insulin infusion set study.<|>8)\n##\n("relationship"<|>DORI KHAKPOUR<|> *************** index/graph/extractors/graph/graph_extractor.py: calling LLM
⠴ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
└── extract_graph
    └── Verb extract_graph ━━━━━━━━━━━━━╺━━━━━━━━━━━━━━━━━━━━━━━━━━  33% -:--:-- 0:00:582024-12-15 21:53:44,780 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:53:44,780 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:53:44,780 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={}
2024-12-15 21:53:44,780 - DataikuChatLLM - INFO - DataikuChatLLM: Response text: ("entity"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>ORGANIZATION<|>Icahn School of Medicine at Mt. Sinai is a medical school in New York, involved in clinical research and education, particularly noted for studies in diabetes care.)
##
("entity"<|>MAYO CLINIC<|>ORGANIZATION<|>Mayo Clinic is a nonprofit medical practice and medical research group based in Rochester, Minnesota, recognized for its patient care and research in various health conditions, including diabetes.)
##
("entity"<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>ORGANIZATION<|>SUNY Upstate Medical University is a university specializing in health sciences located in Syracuse, New York, actively recruiting participants for studies in diabetes treatment.)
##
("entity"<|>MASSACHUSETTS GENERAL HOSPITAL<|>ORGANIZATION<|>Massachusetts General Hospital is a teaching hospital in Boston, Massachusetts, known for its healthcare services and participation in clinical trials, particularly for diabetes.)
##
("entity"<|>TANDEM DIABETES CARE, INC.<|>ORGANIZATION<|>Tandem Diabetes Care, Inc. is a medical device company that specializes in insulin delivery systems for diabetes, sponsoring studies to support their products.)
##
("entity"<|>ALAYNE LEHMAN<|>PERSON<|>Alayne Lehman is the study director at Capillary Biomedical, overseeing the study related to the Extended Wear Insulin Infusion Set during home use in people with Type 1 Diabetes.)
##
("entity"<|>YOGISH KUDVA<|>PERSON<|>Yogish Kudva is the principal investigator at Mayo Clinic for studies related to diabetes.)
##
("entity"<|>SUZAN BZDICK<|>PERSON<|>Suzan Bzdick is a registered nurse and a contact person for studies at SUNY Upstate Medical University.)
##
("entity"<|>RUTH WEINSTOCK<|>PERSON<|>Ruth Weinstock is a principal investigator focused on diabetes research at SUNY Upstate Medical University.)
##
("entity"<|>COREY KUREK<|>PERSON<|>Corey Kurek is a contact person for studies at Mayo Clinic, providing information related to diabetes clinical trials.)
##
("entity"<|>TYPE 1 DIABETES<|>EVENT<|>Type 1 Diabetes is a chronic condition that affects the way the body processes blood sugar (glucose), commonly the focus of clinical studies and trials.)
##
("entity"<|>OPEN, SINGLE ARM, PROSPECTIVE MULTICENTER STUDY<|>EVENT<|>This study aims to collect clinical data to support the use of an investigational Extended Wear Insulin Infusion Set in people with Type 1 Diabetes.)
##
("relationship"<|>ALAYNE LEHMAN<|>TANDEM DIABETES CARE, INC.<|>Alayne Lehman is associated with Tandem Diabetes Care, Inc. as the study director for research on diabetes management.<|>8)
##
("relationship"<|>YOGISH KUDVA<|>MAYO CLINIC<|>Yogish Kudva is the principal investigator for diabetes studies at Mayo Clinic, linking him directly to the organization.<|>7)
##
("relationship"<|>SUZAN BZDICK<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>Suzan Bzdick is a contact person for diabetes studies at SUNY Upstate Medical University, establishing her relationship with the organization.<|>7)
##
("relationship"<|>RUTH WEINSTOCK<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>Ruth Weinstock is the principal investigator at SUNY Upstate Medical University, connecting her to the organization and its research efforts.<|>7)
##
("relationship"<|>COREY KUREK<|>MAYO CLINIC<|>Corey Kurek serves as a contact for diabetes studies at Mayo Clinic, thereby linking him to the organization.<|>7)
##
("relationship"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>TYPE 1 DIABETES<|>Icahn School of Medicine at Mt. Sinai participates in clinical studies focused on Type 1 Diabetes, demonstrating a direct relationship.<|>6)
##
("relationship"<|>MAYO CLINIC<|>TYPE 1 DIABETES<|>Mayo Clinic conducts research and trials specifically aimed at improving treatment for Type 1 Diabetes, establishing a clear relationship.<|>6)
##
("relationship"<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>TYPE 1 DIABETES<|>SUNY Upstate Medical University is actively recruiting for studies investigating Type 1 Diabetes, denoting a direct connection.<|>6)
##
("relationship"<|>MASSACHUSETTS GENERAL HOSPITAL<|>TYPE 1 DIABETES<|>Massachusetts General Hospital engages in diabetes research, particularly focusing on Type 1 Diabetes studies.<|>6)
 *************** index/graph/extractors/graph/graph_extractor.py: for i in range, calling LLM
⠧ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
└── extract_graph
    └── Verb extract_graph ━━━━━━━━━━━━━╺━━━━━━━━━━━━━━━━━━━━━━━━━━  33% -:--:-- 0:00:592024-12-15 21:53:45,599 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:53:45,599 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:53:45,600 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={'name': 'extract-continuation-0', 'history': [{'content': '\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity\'s attributes and activities\nFormat each entity as ("entity"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as ("relationship"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis\'s Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n("entity"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n("entity"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n("entity"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis\'s money supply)\n##\n("relationship"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal\'s (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation\'s debut on the public markets isn\'t indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n("entity"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n("entity"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n("relationship"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad\'s capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia\'s capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia\'s Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n("entity"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n("entity"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n("entity"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n("entity"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n("entity"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n("entity"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n("entity"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia\'s Alhamia Prison)\n##\n("entity"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n("entity"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n("entity"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n("relationship"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n("relationship"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: , NA | Icahn School of Medicine at Mt. Sinai (NOT_YET_RECRUITING), New York, New York, 10029, United States - Camilla Levister, MS, ANCP-C (PRINCIPAL_INVESTIGATOR), NA, NA | Denisa Tamarez (CONTACT), 212-241-9089, denisa.tamarez@mssm.edu | Mayo Clinic (NOT_YET_RECRUITING), Rochester, Minnesota, 55905, United States - Yogish Kudva, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Corey Kurek (CONTACT), 507-255-0316, reid.corey@mayo.edu | SUNY Upstate Medical University (RECRUITING), Syracuse, New York, 13210, United States - Suzan Bzdick, RN, CDCES (CONTACT), 315-464-9006, bzdicks@upstate.edu | Ruth Weinstock, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Massachusetts General Hospital (NOT_YET_RECRUITING), Boston, Massachusetts, 2114, United States - Melissa Putman, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Amy Sabean (CONTACT), 617-726-1729, asabean@mgh.harvard.edu\n# conditions\nType1diabetes\n# study_corpus\nNCTId: NCT06273124\n\nStatus: RECRUITING\n\nSponsor: Tandem Diabetes Care, Inc.\n\nPhase: [\'NA\']\n\nTitle\nOpen, Single Arm, Prospective, Multicenter Study of an Investigational Extended Wear Insulin Infusion Set During Home Use in People With Type 1 Diabetes\n\nSummary\nThe purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS).\n\nParticipants will be asked to:\n\n1. Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods\n2. Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL for one hour\n\nOfficials: Alayne Lehman, RN, MS - Capillary Biomedical (STUDY_DIRECTOR)Conditions:Type1diabetesEnrollment count: 260\n\nEligibility Criteria\nInclusion Criteria:\n\n* Inclusion Criteria:\n\n  1. Age 18 to 80 years old inclusive\n  2. Generally in good health, as determined by the investigator\n  3. Living in the United States with no plans to move outside the United States during the study\n  4. Diagnosis of T1D for at least 12 months\n  5. Minimum of 6 months of insulin pump experience and at least 3 months of current experience with a Tandem pump\n  6. Using Tandem t:slim X2 insulin pump with Control-IQ technology for a minimum of 1 month at the time of enrollment\n  7. Minimum of 14 days of Control-IQ data immediately preceding screening that demonstrate pump use compliance, including at least 85% of time with Control-IQ technology active\n  8. HbA1c \\<9.0% in the last 6 months.\n  9. Willing to implement and adhere to pump alert/alarm settings on a study-provided pump as instructed during the study\n  10. Willing to wear each investigational infusion set for up to 7 days during each of the 12 consecutive wear periods in the study\n  11. Willing to perform blood ketone and blood glucose (fingerstick) measurements as directed using provided ketone and blood glucose meters and strips\n  12. Access to internet for required periodic uploads of study device data\n  13. BMI in the range 18-35 kg/m2, both inclusive\n  14. Currently using one of the following insulins with no expectation of a need to change insulin type during the study:\n\n      1. Humalog™\\* (insulin lispro)\n      2. NovoLog™\\* (insulin aspart)\n  15. Using Humalog™ insulin lispro or NovoLog™ insulin aspart for a minimum of 1 month at the time of enrollment\n  16. Willing to change insulin cartridge every 48-72 hours, as recommended by patient\'s healthcare provider during the study\n  17. Has routine access to a smart phone e.g., ability to receive text messages\n  18. Has the ability to understand and comply with protocol procedures and to provide informed consent (i.e., English proficient in both verbal and written communication)\n\nExclusion Criteria:\n\n1. Concurrent use of any non-insulin glucose-lowering agent, other than metformin (for example, GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas)\n2. Female subject is pregnant, planning to become pregnant, or not using adequate method of contraception\n3. Episodes of severe hypoglycemia in the last 6 months resulting in:\n\n   1. Medical Assistance (i.e., paramedics, hospital evaluation or hospitalization)\n   2. Loss of consciousness\n   3. Seizures\n4. One or more episodes of diabetic ketoacidosis (DKA) in the last 6 months requiring hospitalization\n5. Currently on a ketogenic or low-carbohydrate diet of less than 60 grams of carbohydrates per day, or intending to begin one during the study period\n6. Known cardiovascular disease considered to be clinically relevant by the investigator\n7. Known history of any of the following conditions:\n\n   1\n######################\nOutput:', 'role': 'user'}, ChatCompletionMessage(content='("entity"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>ORGANIZATION<|>Icahn School of Medicine at Mt. Sinai is a medical school in New York, involved in clinical research and education, particularly noted for studies in diabetes care.)\n##\n("entity"<|>MAYO CLINIC<|>ORGANIZATION<|>Mayo Clinic is a nonprofit medical practice and medical research group based in Rochester, Minnesota, recognized for its patient care and research in various health conditions, including diabetes.)\n##\n("entity"<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>ORGANIZATION<|>SUNY Upstate Medical University is a university specializing in health sciences located in Syracuse, New York, actively recruiting participants for studies in diabetes treatment.)\n##\n("entity"<|>MASSACHUSETTS GENERAL HOSPITAL<|>ORGANIZATION<|>Massachusetts General Hospital is a teaching hospital in Boston, Massachusetts, known for its healthcare services and participation in clinical trials, particularly for diabetes.)\n##\n("entity"<|>TANDEM DIABETES CARE, INC.<|>ORGANIZATION<|>Tandem Diabetes Care, Inc. is a medical device company that specializes in insulin delivery systems for diabetes, sponsoring studies to support their products.)\n##\n("entity"<|>ALAYNE LEHMAN<|>PERSON<|>Alayne Lehman is the study director at Capillary Biomedical, overseeing the study related to the Extended Wear Insulin Infusion Set during home use in people with Type 1 Diabetes.)\n##\n("entity"<|>YOGISH KUDVA<|>PERSON<|>Yogish Kudva is the principal investigator at Mayo Clinic for studies related to diabetes.)\n##\n("entity"<|>SUZAN BZDICK<|>PERSON<|>Suzan Bzdick is a registered nurse and a contact person for studies at SUNY Upstate Medical University.)\n##\n("entity"<|>RUTH WEINSTOCK<|>PERSON<|>Ruth Weinstock is a principal investigator focused on diabetes research at SUNY Upstate Medical University.)\n##\n("entity"<|>COREY KUREK<|>PERSON<|>Corey Kurek is a contact person for studies at Mayo Clinic, providing information related to diabetes clinical trials.)\n##\n("entity"<|>TYPE 1 DIABETES<|>EVENT<|>Type 1 Diabetes is a chronic condition that affects the way the body processes blood sugar (glucose), commonly the focus of clinical studies and trials.)\n##\n("entity"<|>OPEN, SINGLE ARM, PROSPECTIVE MULTICENTER STUDY<|>EVENT<|>This study aims to collect clinical data to support the use of an investigational Extended Wear Insulin Infusion Set in people with Type 1 Diabetes.)\n##\n("relationship"<|>ALAYNE LEHMAN<|>TANDEM DIABETES CARE, INC.<|>Alayne Lehman is associated with Tandem Diabetes Care, Inc. as the study director for research on diabetes management.<|>8)\n##\n("relationship"<|>YOGISH KUDVA<|>MAYO CLINIC<|>Yogish Kudva is the principal investigator for diabetes studies at Mayo Clinic, linking him directly to the organization.<|>7)\n##\n("relationship"<|>SUZAN BZDICK<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>Suzan Bzdick is a contact person for diabetes studies at SUNY Upstate Medical University, establishing her relationship with the organization.<|>7)\n##\n("relationship"<|>RUTH WEINSTOCK<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>Ruth Weinstock is the principal investigator at SUNY Upstate Medical University, connecting her to the organization and its research efforts.<|>7)\n##\n("relationship"<|>COREY KUREK<|>MAYO CLINIC<|>Corey Kurek serves as a contact for diabetes studies at Mayo Clinic, thereby linking him to the organization.<|>7)\n##\n("relationship"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>TYPE 1 DIABETES<|>Icahn School of Medicine at Mt. Sinai participates in clinical studies focused on Type 1 Diabetes, demonstrating a direct relationship.<|>6)\n##\n("relationship"<|>MAYO CLINIC<|>TYPE 1 DIABETES<|>Mayo Clinic conducts research and trials specifically aimed at improving treatment for Type 1 Diabetes, establishing a clear relationship.<|>6)\n##\n("relationship"<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>TYPE 1 DIABETES<|>SUNY Upstate Medical University is actively recruiting for studies investigating Type 1 Diabetes, denoting a direct connection.<|>6)\n##\n("relationship"<|>MASSACHUSETTS GENERAL HOSPITAL<|>TYPE 1 DIABETES<|>Massachusetts General Hospital engages in diabetes research, particularly focusing on Type 1 Diabetes studies.<|>6)\n##\n("relationship"<|>TANDEM DIABETES CARE, INC.<|>OPEN, SINGLE ARM, PROSPECTIVE MULTICENTER STUDY<|>Tandem Diabetes Care, Inc. sponsors the clinical study evaluating the Extended Wear Insulin Infusion Set for Type 1 Diabetes patients.<|>8)\n<|COMPLETE|>', refusal=None, role='assistant', audio=None, function_call=None, tool_calls=[], name=None)]}
2024-12-15 21:53:45,601 - DataikuChatLLM - INFO - DataikuChatLLM: Response text: Please provide the previously extracted types so that I can assist you with matching entities and relationships accordingly.
2024-12-15 21:53:45,601 - DataikuChatLLM - INFO - DataikuChatLLM: history=[{'content': '\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity\'s attributes and activities\nFormat each entity as ("entity"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as ("relationship"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis\'s Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n("entity"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n("entity"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n("entity"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis\'s money supply)\n##\n("relationship"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal\'s (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation\'s debut on the public markets isn\'t indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n("entity"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n("entity"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n("relationship"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad\'s capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia\'s capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia\'s Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n("entity"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n("entity"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n("entity"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n("entity"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n("entity"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n("entity"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n("entity"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia\'s Alhamia Prison)\n##\n("entity"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n("entity"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n("entity"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n("relationship"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n("relationship"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: , NA | Icahn School of Medicine at Mt. Sinai (NOT_YET_RECRUITING), New York, New York, 10029, United States - Camilla Levister, MS, ANCP-C (PRINCIPAL_INVESTIGATOR), NA, NA | Denisa Tamarez (CONTACT), 212-241-9089, denisa.tamarez@mssm.edu | Mayo Clinic (NOT_YET_RECRUITING), Rochester, Minnesota, 55905, United States - Yogish Kudva, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Corey Kurek (CONTACT), 507-255-0316, reid.corey@mayo.edu | SUNY Upstate Medical University (RECRUITING), Syracuse, New York, 13210, United States - Suzan Bzdick, RN, CDCES (CONTACT), 315-464-9006, bzdicks@upstate.edu | Ruth Weinstock, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Massachusetts General Hospital (NOT_YET_RECRUITING), Boston, Massachusetts, 2114, United States - Melissa Putman, MD (PRINCIPAL_INVESTIGATOR), NA, NA | Amy Sabean (CONTACT), 617-726-1729, asabean@mgh.harvard.edu\n# conditions\nType1diabetes\n# study_corpus\nNCTId: NCT06273124\n\nStatus: RECRUITING\n\nSponsor: Tandem Diabetes Care, Inc.\n\nPhase: [\'NA\']\n\nTitle\nOpen, Single Arm, Prospective, Multicenter Study of an Investigational Extended Wear Insulin Infusion Set During Home Use in People With Type 1 Diabetes\n\nSummary\nThe purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS).\n\nParticipants will be asked to:\n\n1. Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods\n2. Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL for one hour\n\nOfficials: Alayne Lehman, RN, MS - Capillary Biomedical (STUDY_DIRECTOR)Conditions:Type1diabetesEnrollment count: 260\n\nEligibility Criteria\nInclusion Criteria:\n\n* Inclusion Criteria:\n\n  1. Age 18 to 80 years old inclusive\n  2. Generally in good health, as determined by the investigator\n  3. Living in the United States with no plans to move outside the United States during the study\n  4. Diagnosis of T1D for at least 12 months\n  5. Minimum of 6 months of insulin pump experience and at least 3 months of current experience with a Tandem pump\n  6. Using Tandem t:slim X2 insulin pump with Control-IQ technology for a minimum of 1 month at the time of enrollment\n  7. Minimum of 14 days of Control-IQ data immediately preceding screening that demonstrate pump use compliance, including at least 85% of time with Control-IQ technology active\n  8. HbA1c \\<9.0% in the last 6 months.\n  9. Willing to implement and adhere to pump alert/alarm settings on a study-provided pump as instructed during the study\n  10. Willing to wear each investigational infusion set for up to 7 days during each of the 12 consecutive wear periods in the study\n  11. Willing to perform blood ketone and blood glucose (fingerstick) measurements as directed using provided ketone and blood glucose meters and strips\n  12. Access to internet for required periodic uploads of study device data\n  13. BMI in the range 18-35 kg/m2, both inclusive\n  14. Currently using one of the following insulins with no expectation of a need to change insulin type during the study:\n\n      1. Humalog™\\* (insulin lispro)\n      2. NovoLog™\\* (insulin aspart)\n  15. Using Humalog™ insulin lispro or NovoLog™ insulin aspart for a minimum of 1 month at the time of enrollment\n  16. Willing to change insulin cartridge every 48-72 hours, as recommended by patient\'s healthcare provider during the study\n  17. Has routine access to a smart phone e.g., ability to receive text messages\n  18. Has the ability to understand and comply with protocol procedures and to provide informed consent (i.e., English proficient in both verbal and written communication)\n\nExclusion Criteria:\n\n1. Concurrent use of any non-insulin glucose-lowering agent, other than metformin (for example, GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas)\n2. Female subject is pregnant, planning to become pregnant, or not using adequate method of contraception\n3. Episodes of severe hypoglycemia in the last 6 months resulting in:\n\n   1. Medical Assistance (i.e., paramedics, hospital evaluation or hospitalization)\n   2. Loss of consciousness\n   3. Seizures\n4. One or more episodes of diabetic ketoacidosis (DKA) in the last 6 months requiring hospitalization\n5. Currently on a ketogenic or low-carbohydrate diet of less than 60 grams of carbohydrates per day, or intending to begin one during the study period\n6. Known cardiovascular disease considered to be clinically relevant by the investigator\n7. Known history of any of the following conditions:\n\n   1\n######################\nOutput:', 'role': 'user'}, ChatCompletionMessage(content='("entity"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>ORGANIZATION<|>Icahn School of Medicine at Mt. Sinai is a medical school in New York, involved in clinical research and education, particularly noted for studies in diabetes care.)\n##\n("entity"<|>MAYO CLINIC<|>ORGANIZATION<|>Mayo Clinic is a nonprofit medical practice and medical research group based in Rochester, Minnesota, recognized for its patient care and research in various health conditions, including diabetes.)\n##\n("entity"<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>ORGANIZATION<|>SUNY Upstate Medical University is a university specializing in health sciences located in Syracuse, New York, actively recruiting participants for studies in diabetes treatment.)\n##\n("entity"<|>MASSACHUSETTS GENERAL HOSPITAL<|>ORGANIZATION<|>Massachusetts General Hospital is a teaching hospital in Boston, Massachusetts, known for its healthcare services and participation in clinical trials, particularly for diabetes.)\n##\n("entity"<|>TANDEM DIABETES CARE, INC.<|>ORGANIZATION<|>Tandem Diabetes Care, Inc. is a medical device company that specializes in insulin delivery systems for diabetes, sponsoring studies to support their products.)\n##\n("entity"<|>ALAYNE LEHMAN<|>PERSON<|>Alayne Lehman is the study director at Capillary Biomedical, overseeing the study related to the Extended Wear Insulin Infusion Set during home use in people with Type 1 Diabetes.)\n##\n("entity"<|>YOGISH KUDVA<|>PERSON<|>Yogish Kudva is the principal investigator at Mayo Clinic for studies related to diabetes.)\n##\n("entity"<|>SUZAN BZDICK<|>PERSON<|>Suzan Bzdick is a registered nurse and a contact person for studies at SUNY Upstate Medical University.)\n##\n("entity"<|>RUTH WEINSTOCK<|>PERSON<|>Ruth Weinstock is a principal investigator focused on diabetes research at SUNY Upstate Medical University.)\n##\n("entity"<|>COREY KUREK<|>PERSON<|>Corey Kurek is a contact person for studies at Mayo Clinic, providing information related to diabetes clinical trials.)\n##\n("entity"<|>TYPE 1 DIABETES<|>EVENT<|>Type 1 Diabetes is a chronic condition that affects the way the body processes blood sugar (glucose), commonly the focus of clinical studies and trials.)\n##\n("entity"<|>OPEN, SINGLE ARM, PROSPECTIVE MULTICENTER STUDY<|>EVENT<|>This study aims to collect clinical data to support the use of an investigational Extended Wear Insulin Infusion Set in people with Type 1 Diabetes.)\n##\n("relationship"<|>ALAYNE LEHMAN<|>TANDEM DIABETES CARE, INC.<|>Alayne Lehman is associated with Tandem Diabetes Care, Inc. as the study director for research on diabetes management.<|>8)\n##\n("relationship"<|>YOGISH KUDVA<|>MAYO CLINIC<|>Yogish Kudva is the principal investigator for diabetes studies at Mayo Clinic, linking him directly to the organization.<|>7)\n##\n("relationship"<|>SUZAN BZDICK<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>Suzan Bzdick is a contact person for diabetes studies at SUNY Upstate Medical University, establishing her relationship with the organization.<|>7)\n##\n("relationship"<|>RUTH WEINSTOCK<|>SUNY UPSTATE MEDICAL UNIVERSITY<|>Ruth Weinstock is the principal investigator at SUNY Upstate Medical University, connecting her to the organization and its research efforts.<|>7)\n##\n("relationship"<|>COREY KUREK<|>MAYO CLINIC<|>Corey Kurek serves as a contact for diabetes studies at Mayo Clinic, thereby linking him to the organization.<|>7)\n##\n("relationship"<|>ICAHN SCHOOL OF MEDICINE AT MT. SINAI<|>TYPE 1 DIABETES<|>Icahn School of Medicine at Mt. Sinai participates in clinical studies focused on Type 1 Diabetes, demonstrating a direct relationship.<|>6)\n##\n("relationship"<|>MAYO CLINIC<|>TYPE 1 DIABETES<|>Mayo Clinic conducts research and trials specifically aimed at improving treatment for Type 1 Diabetes, establishing a clear relationship.<|>6)\n# *************** index/graph/extractors/graph/graph_extractor.py: calling LLM
⠼ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
└── extract_graph
    └── Verb extract_graph ━━━━━━━━━━━━━━━━━━━━━━━━━━╸━━━━━━━━━━━━━  67% 0:00:24 0:01:132024-12-15 21:53:59,552 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:53:59,552 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:53:59,552 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={}
2024-12-15 21:53:59,552 - DataikuChatLLM - INFO - DataikuChatLLM: Response text: ("entity"<|>CAPILLARY BIOMEDICAL<|>ORGANIZATION<|>Capillary Biomedical is the organization conducting a multi-center clinical study involving adults with Type 1 diabetes and using a Tandem t:slim X2 insulin pump.)
##
("entity"<|>TANDEM T:SLIM X2 INSULIN PUMP<|>ORGANIZATION<|>The Tandem t:slim X2 insulin pump is a medical device used for insulin delivery in patients with diabetes, featuring Control-IQ technology and continuous Glucose Monitoring.)
##
("entity"<|>TYPE 1 DIABETES<|>EVENT<|>Type 1 Diabetes is a chronic condition where the pancreas produces little or no insulin, leading to the need for continuous insulin delivery through devices like insulin pumps.)
##
("entity"<|>UNITED STATES<|>GEO<|>The United States is the country where the clinical study is taking place to enroll participants for the Type 1 diabetes study.)
##
("entity"<|>STUDY START DATE<|>EVENT<|>The study is scheduled to commence on March 7, 2024, involving participants with Type 1 diabetes.)
##
("entity"<|>STUDY COMPLETION DATE<|>EVENT<|>The study is set to be completed by January 15, 2025, after evaluating the effects of the infusion set on participants.)
##
("entity"<|>INVESTIGATIONAL CENTERS<|>ORGANIZATION<|>The investigational centers are the locations where the study participants will be enrolled and monitored during the clinical trial.)
##
("entity"<|>PARTICIPANTS<|>PERSON<|>Participants are individuals aged 18-80 with Type 1 diabetes who will be involved in the clinical study, with up to 300 expected across the U.S.)
##
("entity"<|>CONTROL-IQ TECHNOLOGY<|>ORGANIZATION<|>Control-IQ technology is the system used in the Tandem t:slim X2 insulin pump to automatically adjust insulin delivery based on continuous glucose monitoring.)
##
("entity"<|>HEALTH CARE PROVIDER<|>PERSON<|>Health care providers are professionals responsible for advising participants on insulin cartridge changes and overseeing their treatment in the study.)

("relationship"<|>PARTICIPANTS<|>CAPILLARY BIOMEDICAL<|>Participants are involved in a clinical study conducted by Capillary Biomedical to evaluate the extended wear infusion set for diabetes management.<|>8)
##
("relationship"<|>PARTICIPANTS<|>TANDEM T:SLIM X2 INSULIN PUMP<|>Participants will use the Tandem t:slim X2 insulin pump as part of the diabetes management in the study.<|>8)
##
("relationship"<|>CAPILLARY BIOMEDICAL<|>INVESTIGATIONAL CENTERS<|>Capillary Biomedical will conduct the study at various investigational centers across the United States<|>7)
##
("relationship"<|>PARTICIPANTS<|>CONTROL-IQ TECHNOLOGY<|>Participants will benefit from the Control-IQ technology incorporated in the Tandem t:slim X2 insulin pump during the study<|>8)
##
("relationship"<|>HEALTH CARE PROVIDER<|>PARTICIPANTS<|>Health care providers will guide participants in insulin management and cartridge changes throughout the study<|>6)
##
("relationship"<|>UNITED STATES<|>PARTICIPANTS<|>Participants will be recruited from multiple sites across the United States for the clinical study<|>5)
 *************** index/graph/extractors/graph/graph_extractor.py: for i in range, calling LLM
⠴ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
└── extract_graph
    └── Verb extract_graph ━━━━━━━━━━━━━━━━━━━━━━━━━━╸━━━━━━━━━━━━━  67% 0:00:24 0:01:132024-12-15 21:54:00,400 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:54:00,400 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:54:00,401 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={'name': 'extract-continuation-0', 'history': [{'content': '\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity\'s attributes and activities\nFormat each entity as ("entity"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as ("relationship"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis\'s Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n("entity"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n("entity"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n("entity"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis\'s money supply)\n##\n("relationship"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal\'s (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation\'s debut on the public markets isn\'t indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n("entity"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n("entity"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n("relationship"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad\'s capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia\'s capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia\'s Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n("entity"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n("entity"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n("entity"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n("entity"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n("entity"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n("entity"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n("entity"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia\'s Alhamia Prison)\n##\n("entity"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n("entity"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n("entity"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n("relationship"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n("relationship"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 2. Loss of consciousness\n   3. Seizures\n4. One or more episodes of diabetic ketoacidosis (DKA) in the last 6 months requiring hospitalization\n5. Currently on a ketogenic or low-carbohydrate diet of less than 60 grams of carbohydrates per day, or intending to begin one during the study period\n6. Known cardiovascular disease considered to be clinically relevant by the investigator\n7. Known history of any of the following conditions:\n\n   1. Cushing\'s Disease\n   2. Pancreatic islet cell tumor\n   3. Insulinoma\n   4. Lipodystrophy\n   5. Extensive lipohypertrophy, as assessed by the investigator\n8. Currently undergoing treatment with:\n\n   1. Systemic oral or intravenous corticosteroids (current or within the last 8 weeks from screening),\n   2. Thyroid hormones, unless use has been stable during the past 3 months\n9. Significant history of any of the following, that in the opinion of the investigator would compromise safety or successful study participation:\n\n   1. Alcoholism\n   2. Drug abuse\n10. Significant acute or chronic illness, that in the opinion of the investigator might interfere with safety or integrity of study results\n11. Current participation in another clinical drug or device study\n12. Immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is a study site personnel directly affiliated with this study or who is an employee of Capillary BiomedicalStart Date:2024-03-07Completion Date:2025-01-15\n\nDetailed Description\nThis is a multi-center, single-arm, prospective study of an extended wear infusion set in adults with Type 1 diabetes using a Tandem t:slim X2 insulin pump with Control-IQ technology with continuous Glucose Monitoring (CGM). Up to 300 participants across the United States age 18-80 will be enrolled in up to 20 investigational centers. Participants will change insulin cartridge every 48 to 72 hours as recommended by their health care provider. Participants will be expected to participate in the study for approximately 12-16 weeks.\n######################\nOutput:', 'role': 'user'}, ChatCompletionMessage(content='("entity"<|>CAPILLARY BIOMEDICAL<|>ORGANIZATION<|>Capillary Biomedical is the organization conducting a multi-center clinical study involving adults with Type 1 diabetes and using a Tandem t:slim X2 insulin pump.)\n##\n("entity"<|>TANDEM T:SLIM X2 INSULIN PUMP<|>ORGANIZATION<|>The Tandem t:slim X2 insulin pump is a medical device used for insulin delivery in patients with diabetes, featuring Control-IQ technology and continuous Glucose Monitoring.)\n##\n("entity"<|>TYPE 1 DIABETES<|>EVENT<|>Type 1 Diabetes is a chronic condition where the pancreas produces little or no insulin, leading to the need for continuous insulin delivery through devices like insulin pumps.)\n##\n("entity"<|>UNITED STATES<|>GEO<|>The United States is the country where the clinical study is taking place to enroll participants for the Type 1 diabetes study.)\n##\n("entity"<|>STUDY START DATE<|>EVENT<|>The study is scheduled to commence on March 7, 2024, involving participants with Type 1 diabetes.)\n##\n("entity"<|>STUDY COMPLETION DATE<|>EVENT<|>The study is set to be completed by January 15, 2025, after evaluating the effects of the infusion set on participants.)\n##\n("entity"<|>INVESTIGATIONAL CENTERS<|>ORGANIZATION<|>The investigational centers are the locations where the study participants will be enrolled and monitored during the clinical trial.)\n##\n("entity"<|>PARTICIPANTS<|>PERSON<|>Participants are individuals aged 18-80 with Type 1 diabetes who will be involved in the clinical study, with up to 300 expected across the U.S.)\n##\n("entity"<|>CONTROL-IQ TECHNOLOGY<|>ORGANIZATION<|>Control-IQ technology is the system used in the Tandem t:slim X2 insulin pump to automatically adjust insulin delivery based on continuous glucose monitoring.)\n##\n("entity"<|>HEALTH CARE PROVIDER<|>PERSON<|>Health care providers are professionals responsible for advising participants on insulin cartridge changes and overseeing their treatment in the study.)\n\n("relationship"<|>PARTICIPANTS<|>CAPILLARY BIOMEDICAL<|>Participants are involved in a clinical study conducted by Capillary Biomedical to evaluate the extended wear infusion set for diabetes management.<|>8)\n##\n("relationship"<|>PARTICIPANTS<|>TANDEM T:SLIM X2 INSULIN PUMP<|>Participants will use the Tandem t:slim X2 insulin pump as part of the diabetes management in the study.<|>8)\n##\n("relationship"<|>CAPILLARY BIOMEDICAL<|>INVESTIGATIONAL CENTERS<|>Capillary Biomedical will conduct the study at various investigational centers across the United States<|>7)\n##\n("relationship"<|>PARTICIPANTS<|>CONTROL-IQ TECHNOLOGY<|>Participants will benefit from the Control-IQ technology incorporated in the Tandem t:slim X2 insulin pump during the study<|>8)\n##\n("relationship"<|>HEALTH CARE PROVIDER<|>PARTICIPANTS<|>Health care providers will guide participants in insulin management and cartridge changes throughout the study<|>6)\n##\n("relationship"<|>UNITED STATES<|>PARTICIPANTS<|>Participants will be recruited from multiple sites across the United States for the clinical study<|>5)\n##\n("relationship"<|>STUDY START DATE<|>STUDY COMPLETION DATE<|>The study will begin on March 7, 2024, and is expected to end on January 15, 2025<|>9)\n<|COMPLETE|>', refusal=None, role='assistant', audio=None, function_call=None, tool_calls=[], name=None)]}
2024-12-15 21:54:00,402 - DataikuChatLLM - INFO - DataikuChatLLM: Response text: Of course! Please provide the previously extracted types so I can help you identify and add any relevant entities and relationships.
2024-12-15 21:54:00,402 - DataikuChatLLM - INFO - DataikuChatLLM: history=[{'content': '\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity\'s attributes and activities\nFormat each entity as ("entity"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as ("relationship"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis\'s Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n("entity"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n("entity"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n("entity"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis\'s money supply)\n##\n("relationship"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal\'s (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation\'s debut on the public markets isn\'t indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n("entity"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n("entity"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n("relationship"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad\'s capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia\'s capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia\'s Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n("entity"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n("entity"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n("entity"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n("entity"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n("entity"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n("entity"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n("entity"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia\'s Alhamia Prison)\n##\n("entity"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n("entity"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n("entity"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n("relationship"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n("relationship"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n("relationship"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n("relationship"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 2. Loss of consciousness\n   3. Seizures\n4. One or more episodes of diabetic ketoacidosis (DKA) in the last 6 months requiring hospitalization\n5. Currently on a ketogenic or low-carbohydrate diet of less than 60 grams of carbohydrates per day, or intending to begin one during the study period\n6. Known cardiovascular disease considered to be clinically relevant by the investigator\n7. Known history of any of the following conditions:\n\n   1. Cushing\'s Disease\n   2. Pancreatic islet cell tumor\n   3. Insulinoma\n   4. Lipodystrophy\n   5. Extensive lipohypertrophy, as assessed by the investigator\n8. Currently undergoing treatment with:\n\n   1. Systemic oral or intravenous corticosteroids (current or within the last 8 weeks from screening),\n   2. Thyroid hormones, unless use has been stable during the past 3 months\n9. Significant history of any of the following, that in the opinion of the investigator would compromise safety or successful study participation:\n\n   1. Alcoholism\n   2. Drug abuse\n10. Significant acute or chronic illness, that in the opinion of the investigator might interfere with safety or integrity of study results\n11. Current participation in another clinical drug or device study\n12. Immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is a study site personnel directly affiliated with this study or who is an employee of Capillary BiomedicalStart Date:2024-03-07Completion Date:2025-01-15\n\nDetailed Description\nThis is a multi-center, single-arm, prospective study of an extended wear infusion set in adults with Type 1 diabetes using a Tandem t:slim X2 insulin pump with Control-IQ technology with continuous Glucose Monitoring (CGM). Up to 300 participants across the United States age 18-80 will be enrolled in up to 20 investigational centers. Participants will change insulin cartridge every 48 to 72 hours as recommended by their health care provider. Participants will be expected to participate in the study for approximately 12-16 weeks.\n######################\nOutput:', 'role': 'user'}, ChatCompletionMessage(content='("entity"<|>CAPILLARY BIOMEDICAL<|>ORGANIZATION<|>Capillary Biomedical is the organization conducting a multi-center clinical study involving adults with Type 1 diabetes and using a Tandem t:slim X2 insulin pump.)\n##\n("entity"<|>TANDEM T:SLIM X2 INSULIN PUMP<|>ORGANIZATION<|>The Tandem t:slim X2 insulin pump is a medical device used for insulin delivery in patients with diabetes, featuring Control-IQ technology and continuous Glucose Monitoring.)\n##\n("entity"<|>TYPE 1 DIABETES<|>EVENT<|>Type 1 Diabetes is a chronic condition where the pancreas produces little or no insulin, leading to the need for continuous insulin delivery through devices like insulin pumps.)\n##\n("entity"<|>UNITED STATES<|>GEO<|>The United States is the country where the clinical study is taking place to enroll participants for the Type 1 diabetes study.)\n##\n("entity"<|>STUDY START DATE<|>EVENT<|>The study is scheduled to commence on March 7, 2024, involving participants with Type 1 diabetes.)\n##\n("entity"<|>STUDY COMPLETION DATE<|>EVENT<|>The study is set to be completed by January 15, 2025, after evaluating the effects of the infusion set on participants.)\n##\n("entity"<|>INVESTIGATIONAL CENTERS<|>ORGANIZATION<|>The investigational centers are the locations where the study participants will be enrolled and monitored during the clinical trial.)\n##\n("entity"<|>PARTICIPANTS<|>PERSON<|>Participants are individuals aged 18-80 with Type 1 diabetes who will be involved in the clinical study, with up to 300 expected across the U.S.)\n##\n("entity"<|>CONTROL-IQ TECHNOLOGY<|>ORGANIZATION<|>Control-IQ technology is the system used in the Tandem t:slim X2 insulin pump to automatically adjust insulin delivery based on continuous glucose monitoring.)\n##\n("entity"<|>HEALTH CARE PROVIDER<|>PERSON<|>Health care providers are professionals responsible for advising participants on insulin cartridge changes and overseeing their treatment in the study.)\n\n("relationship"<|>PARTICIPANTS<|>CAPILLARY BIOMEDICAL<|>Participants are involved in a clinical study conducted by Capillary Biomedical to evaluate the extended wear infusion set for diabetes management.<|>8)\n##\n("relationship"<|>PARTICIPANTS<|>TANDEM T:SLIM X2 INSULIN PUMP<|>Participants will use the Tandem t:slim X2 insulin pump as part of the diabetes management in the study.<|>8)\n##\n("relationship"<|>CAPILLARY BIOMEDICAL<|>INVESTIGATIONAL CENTERS<|>Capillary Biomedical will conduct the study at various investigational centers across the United States<|>7)\n##\n("relationship"<|>PARTICIPANTS<|>CONT *************** index/graph/extractors/summarize/description_summary_extractor.py, calling LLM
⠋ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
└── extract_graph2024-12-15 21:54:02,052 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:54:02,052 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:54:02,052 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={'name': 'summarize', 'model_parameters': {'max_tokens': 500}}
2024-12-15 21:54:02,052 - DataikuChatLLM - INFO - DataikuChatLLM: Response text: Tandem Diabetes Care, Inc. is a specialized medical device company that focuses on developing and providing insulin delivery systems for individuals with di *************** index/graph/extractors/summarize/description_summary_extractor.py, calling LLM
⠴ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
└── extract_graph2024-12-15 21:54:03,565 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:54:03,566 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:54:03,566 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={'name': 'summarize', 'model_parameters': {'max_tokens': 500}}
 *************** index/graph/extractors/summarize/description_summary_extractor.py, calling LLM
⠇ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
└── extract_graph2024-12-15 21:54:04,973 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:54:04,973 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:54:04,973 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={'name': 'summarize', 'model_parameters': {'max_tokens': 500}}
 *************** index/graph/extractors/summarize/description_summary_extractor.py, calling LLM
⠋ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
└── extract_graph2024-12-15 21:54:06,493 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:54:06,493 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:54:06,493 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={'name': 'summarize', 'model_parameters': {'max_tokens': 500}}
 *************** index/graph/extractors/summarize/description_summary_extractor.py, calling LLM
⠴ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
└── extract_graph2024-12-15 21:54:08,275 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:54:08,275 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:54:08,275 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={'name': 'summarize', 'model_parameters': {'max_tokens': 500}}
2024-12-15 21:54:08,275 - DataikuChatLLM - INFO - DataikuChatLLM: Response text: Type 1 Diabetes is a chronic condition characterized by the body's inability to effectively process blood sugar (glucose) due to insufficient insulin produc *************** index/graph/extractors/summarize/description_summary_extractor.py, calling LLM
⠇ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
└── extract_graph2024-12-15 21:54:09,435 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:54:09,435 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:54:09,435 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={'name': 'summarize', 'model_parameters': {'max_tokens': 500}}
🚀 extract_graph
Empty DataFrame
Columns: []
Index: []
⠏ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
⠋ GraphRAG Indexer 
/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/hyppo/independence/hhg.py:3: DeprecationWarning: Please import `random` from the `scipy.sparse` namespace; the 
`scipy.sparse.construct` namespace is deprecated and will be removed in SciPy 2.0.0.
  from scipy.sparse.construct import random
/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/numba/core/decorators.py:157: NumbaDeprecationWarning: The keyword argument 'nopython=False' was supplied. From Numba 
0.59.0 the default is True and supplying this argument has no effect.
  warnings.warn(msg, NumbaDeprecationWarning)
🚀 compute_communities
Empty DataFrame
Columns: []
Index: []
⠏ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
⠙ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
🚀 create_final_entities
                                      id  human_readable_id                                              title          type                                        description                                      text_unit_ids
0   fdc16e1b-7185-465a-856f-c05a85527d8e                  0                         TANDEM DIABETES CARE, INC.  ORGANIZATION  Tandem Diabetes Care, Inc. is a specialized me...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
1   70b41654-33b6-495f-a0c3-2b2372fb50db                  1                       ENDOCRINE RESEARCH SOLUTIONS  ORGANIZATION  Endocrine Research Solutions is a clinical sit...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
2   7b451cf7-5baf-4825-b63e-6aac3f1c1c1c                  2                           HENRY FORD HEALTH SYSTEM  ORGANIZATION  Henry Ford Health System is a clinical site th...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
3   f61dd556-ffcd-4523-868d-7b55444b9e49                  3                HOAG MEMORIAL HOSPITAL PRESBYTERIAN  ORGANIZATION  Hoag Memorial Hospital Presbyterian is a clini...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
4   4a8266fd-138a-48a0-9b16-4a9b9494a9f2                  4  INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS...  ORGANIZATION  International Diabetes Center is a clinical si...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
5   a13304cf-c2cb-4c81-8221-2c2f884e23ac                  5                               BARBARA DAVIS CENTER  ORGANIZATION  Barbara Davis Center is a clinical site that i...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
6   27a3e25b-fdb0-4176-a0c6-139faa073623                  6                            NORTHWESTERN UNIVERSITY  ORGANIZATION  Northwestern University is a clinical site tha...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
7   780c7b0c-c278-4000-97e4-8c169fd064bd                  7                   RAINIER CLINICAL RESEARCH CENTER  ORGANIZATION  Rainier Clinical Research Center is a clinical...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
8   a834811e-93a0-4972-b5eb-2f389876d21f                  8                   TEXAS DIABETES AND ENDOCRINOLOGY  ORGANIZATION  Texas Diabetes and Endocrinology is a clinical...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
9   a84decf0-0d65-4953-ad19-c83f2cca1b24                  9                                STANFORD UNIVERSITY  ORGANIZATION  Stanford University is a clinical site that is...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
10  55633dea-f0d9-4e0b-ae6f-00619e8d5ca1                 10                           UNIVERSITY OF WASHINGTON  ORGANIZATION  University of Washington is a clinical site th...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
11  3ebaf5f3-b4bc-4a9a-82a7-db41278c8f70                 11              ICAHN SCHOOL OF MEDICINE AT MT. SINAI  ORGANIZATION  The Icahn School of Medicine at Mt. Sinai is a...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
12  ea30eb6d-f641-4f2c-8256-e267ed8708de                 12                                        MAYO CLINIC  ORGANIZATION  Mayo Clinic is a nonprofit medical practice an...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
13  5dacde3c-06d6-46b3-bf6b-eca07def3802                 13                                      ALAYNE LEHMAN        PERSON  Alayne Lehman is the study director at Capilla...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
14  e166e30f-179f-4820-8126-3f0f5848246b                 14                                        JOHN C REED        PERSON  John C Reed is a principal investigator at End...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
15  462082fb-0b15-4629-87a6-cadf8151c643                 15                                      DAVIDA KRUGER        PERSON  Davida Kruger is a principal investigator at H...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
16  322e4db1-96a2-4f99-9865-20911267126c                 16                                    BRITTANY DENNIS        PERSON  Brittany Dennis is a contact person at Hoag Me...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
17  b586c94f-7961-4396-891a-06d01f767968                 17                                 RICHARD BERGENSTAL        PERSON  Richard Bergenstal is a principal investigator...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
18  a1619c07-938f-42e6-acc6-7e1a8038d6c0                 18                                       KATHRYN LEET        PERSON  Kathryn Leet is a contact at the International...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
19  9802685c-1f4e-4a9a-80b5-36b1bc639031                 19                                     SAMANTHA LANGE        PERSON  Samantha Lange is a contact person at Barbara ...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
20  4df76db6-aa8c-4f1b-85df-969fb44eee60                 20                                         ERIN COBRY        PERSON  Erin Cobry is a principal investigator at Barb...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
21  730156f8-8413-4004-a20c-648304c2a899                 21                                      GRAZIA ALEPPO        PERSON  Grazia Aleppo is a principal investigator at N...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
22  3009b0b1-a68b-40bf-bcab-92ab52e702cd                 22                                       WYATT LARSON        PERSON  Wyatt Larson is a contact at Rainier Clinical ...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
23  58b60626-2e0f-4947-bfcf-320d03c3ff60                 23                                          JEAN CHEN        PERSON  Jean Chen is a principal investigator at Texas...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
24  cdba9e83-e21f-4cd6-9435-f024d9f2b576                 24                                     EMMANUEL LOPEZ        PERSON  Emmanuel Lopez is a contact person at Texas Di...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
25  c0143882-defe-4b18-826b-0eb5c3f2ef51                 25                                         RAYHAN LAL        PERSON  Rayhan Lal is a principal investigator at Stan...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
26  fce60c14-f276-4353-ab57-8f3aedf0b235                 26                                      DORI KHAKPOUR        PERSON  Dori Khakpour is a contact at University of Wa...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
27  9bc66af4-b7fe-4f34-a714-8ff7002a7576                 27                                   CAMILLA LEVISTER        PERSON  Camilla Levister is a principal investigator a...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
28  3b46b3e2-10ef-4c94-921b-28787de9c1bf                 28                                     DENISA TAMAREZ        PERSON  Denisa Tamarez is a contact person at Icahn Sc...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
29  19d40450-a61d-4706-b68e-498bcae6b4c1                 29                    SUNY UPSTATE MEDICAL UNIVERSITY  ORGANIZATION  SUNY Upstate Medical University is a universit...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
30  e2f078f5-de66-4fbc-93eb-fdbf4c82f074                 30                     MASSACHUSETTS GENERAL HOSPITAL  ORGANIZATION  Massachusetts General Hospital is a teaching h...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
31  eac85ef3-26cc-4bc0-8c82-1d06f4f98ab3                 31                                       YOGISH KUDVA        PERSON  Yogish Kudva is the principal investigator at ...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
32  c28c4844-34a7-43eb-87b9-7ecd5c7333a0                 32                                       SUZAN BZDICK        PERSON  Suzan Bzdick is a registered nurse and a conta...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
33  7c4fbd9e-fcb5-4670-abac-f6ef1218fd57                 33                                     RUTH WEINSTOCK        PERSON  Ruth Weinstock is a principal investigator foc...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
34  c0a779f2-a09a-4e28-90e5-1ccaa95ab11b                 34                                        COREY KUREK        PERSON  Corey Kurek is a contact person for studies at...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
35  3355e819-f328-4661-bde5-a03df2ac7e67                 35                                    TYPE 1 DIABETES         EVENT  Type 1 Diabetes is a chronic condition charact...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
36  9840adef-b1ce-4aa7-b167-17c091278104                 36    OPEN, SINGLE ARM, PROSPECTIVE MULTICENTER STUDY         EVENT  This study aims to collect clinical data to su...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
37  35469175-eb9b-4186-930b-cafbd4efb211                 37                               CAPILLARY BIOMEDICAL  ORGANIZATION  Capillary Biomedical is the organization condu...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
38  b8d49b6e-1a86-4780-a7f1-1d86b7d68beb                 38                      TANDEM T:SLIM X2 INSULIN PUMP  ORGANIZATION  The Tandem t:slim X2 insulin pump is a medical...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
39  2a1ed965-11cf-4636-b270-bf9bd6c0dc2d                 39                                      UNITED STATES           GEO  The United States is the country where the cli...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
40  dde4249a-81ec-4b93-95a2-5b04d58d9086                 40                                   STUDY START DATE         EVENT  The study is scheduled to commence on March 7,...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
41  81f90381-bb86-4588-94c9-a4ab26b80e85                 41                              STUDY COMPLETION DATE         EVENT  The study is set to be completed by January 15...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
42  cbec8a5b-fc4e-4319-b8f2-4c9525016026                 42                            INVESTIGATIONAL CENTERS  ORGANIZATION  The investigational centers are the locations ...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
43  43a42910-eb85-4e8f-99cf-d283c1d2e3eb                 43                                       PARTICIPANTS        PERSON  Participants are individuals aged 18-80 with T...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
44  279dad2a-4552-4457-af5d-759a3dc7e843                 44                              CONTROL-IQ TECHNOLOGY  ORGANIZATION  Control-IQ technology is the system used in th...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
45  64c51694-6b9e-4ddb-8451-4e76425d7033                 45                               HEALTH CARE PROVIDER        PERSON  Health care providers are professionals respon...  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
⠙ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
⠹ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
🚀 create_final_relationships
                                      id  human_readable_id                                             source  ... weight combined_degree                                      text_unit_ids
0   f1e50899-600a-41e7-935d-487e92eb0876                  0                         TANDEM DIABETES CARE, INC.  ...   16.0               3  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
1   91eb6138-ea01-442d-91e7-bca42c6c0faf                  1                       ENDOCRINE RESEARCH SOLUTIONS  ...    8.0               2  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
2   f35dd36e-6d62-4b2c-8ce7-0fe2b2f3a7e2                  2                           HENRY FORD HEALTH SYSTEM  ...    8.0               2  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
3   bf54a819-db49-461f-91ac-01bd15eea595                  3                HOAG MEMORIAL HOSPITAL PRESBYTERIAN  ...    7.0               2  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
4   ab26d036-ebf0-4cbc-b731-18f31e4354c6                  4  INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS...  ...    8.0               3  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
5   266722e5-a085-44d9-b11f-4adbd8615582                  5  INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS...  ...    7.0               3  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
6   addc0dc5-0c48-47c4-a496-41be2ac9d10b                  6                               BARBARA DAVIS CENTER  ...    7.0               3  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
7   9a11b370-4b4c-4c6e-b575-e741decda58f                  7                               BARBARA DAVIS CENTER  ...    8.0               3  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
8   26494229-245b-4d54-90a3-b356242a06fa                  8                            NORTHWESTERN UNIVERSITY  ...    8.0               2  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
9   ec06cf94-0270-4fca-9b3b-558bb4fe94ea                  9                   RAINIER CLINICAL RESEARCH CENTER  ...    7.0               2  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
10  428ffb73-c100-4788-a77c-90c21078bdd3                 10                   TEXAS DIABETES AND ENDOCRINOLOGY  ...    8.0               3  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
11  57015ee1-b58b-4a24-942a-ca7679099711                 11                   TEXAS DIABETES AND ENDOCRINOLOGY  ...    7.0               3  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
12  b8be7191-6b66-4fe7-85a4-601c3fa3c8aa                 12                                STANFORD UNIVERSITY  ...    8.0               2  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
13  1fe9d816-7870-44aa-9d20-b03e22d9001d                 13                           UNIVERSITY OF WASHINGTON  ...    7.0               2  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
14  991f6b25-8356-44aa-b807-7d05a4a46845                 14              ICAHN SCHOOL OF MEDICINE AT MT. SINAI  ...    8.0               4  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
15  51abc6ec-6b35-4392-af4d-3ccca1c53f8d                 15              ICAHN SCHOOL OF MEDICINE AT MT. SINAI  ...    7.0               4  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
16  622b7678-b9d7-4a8f-8e67-1d0c798aa393                 16                                        MAYO CLINIC  ...    1.0              10  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...
17  fd0ec259-0786-492c-8487-3dbf2a621650                 17              ICAHN SCHOOL OF MEDICINE AT MT. SINAI  ...    6.0               7  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
18  029f130b-29ba-49eb-823f-daddb0bf04aa                 18                                        MAYO CLINIC  ...    7.0               6  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
19  db3a8788-4574-461c-9d18-abee1538a307                 19                                        MAYO CLINIC  ...    7.0               6  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
20  146c2962-d3b3-47bf-b9c1-f1147a3b8bfd                 20                                        MAYO CLINIC  ...    6.0               9  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
21  fa7bb9ea-3f77-4e85-b41d-5b7d4e8716a9                 21                    SUNY UPSTATE MEDICAL UNIVERSITY  ...    7.0               4  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
22  06ec622c-4655-409b-b58d-643750b3e727                 22                    SUNY UPSTATE MEDICAL UNIVERSITY  ...    7.0               4  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
23  e5ddfcbb-2b27-4e2b-af69-46afe3dbb1a9                 23                    SUNY UPSTATE MEDICAL UNIVERSITY  ...    6.0               7  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
24  bb1b770a-f976-43b9-9c0c-d642588ca90e                 24                     MASSACHUSETTS GENERAL HOSPITAL  ...    6.0               5  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
25  8a6a2afc-7df6-4ba9-bde1-5b03d6ca0bf6                 25                         TANDEM DIABETES CARE, INC.  ...    1.0               3  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...
26  9939511d-d7af-48d4-8065-294a0d4572aa                 26                               CAPILLARY BIOMEDICAL  ...    7.0               2  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
27  dc992570-5299-4a46-81e9-56f39eaccc79                 27                      TANDEM T:SLIM X2 INSULIN PUMP  ...    8.0               5  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
28  cefd0be0-0120-4798-998f-90489313f909                 28                                      UNITED STATES  ...    5.0               5  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
29  772c4a8c-73a0-4c9f-886b-ed6a3b6c3c84                 29                                   STUDY START DATE  ...    1.0               2  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
30  cad59d4a-4633-4a02-9526-1ee4936896d3                 30                                       PARTICIPANTS  ...    8.0               5  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...
31  8ccb29e1-1f0e-4a81-a7c1-1a9cb19a1c70                 31                                       PARTICIPANTS  ...    6.0               5  [616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686f...

[32 rows x 8 columns]
⠸ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
⠼ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
🚀 create_final_communities
                                     id human_readable_id community  parent  ...                                   relationship_ids                                      text_unit_ids      period size
0  9ec1d02b-f544-400d-b806-f82ce2f76b8c                 0         0      -1  ...  [51abc6ec-6b35-4392-af4d-3ccca1c53f8d, 991f6b2...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...  2024-12-15    3
1  cfb7541a-ea81-4186-b531-34e3ec0abd18                 1         1      -1  ...  [029f130b-29ba-49eb-823f-daddb0bf04aa, 622b767...  [07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938a...  2024-12-15    3
2  62dae862-5632-4646-9751-c432391eff05                 2         2      -1  ...               [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...  2024-12-15    2
3  0b58cead-ff2f-4b82-b597-ff91f2ce9e99                 3         3      -1  ...  [06ec622c-4655-409b-b58d-643750b3e727, fa7bb9e...  [50fcd19011dc02899d75146662bd0110ec7409cbfdb06...  2024-12-15    3

[4 rows x 11 columns]
⠼ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
⠴ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
🚀 create_final_nodes
                                      id  human_readable_id                                              title  community  level  degree  x  y
0   fdc16e1b-7185-465a-856f-c05a85527d8e                  0                         TANDEM DIABETES CARE, INC.         -1      0       2  0  0
1   70b41654-33b6-495f-a0c3-2b2372fb50db                  1                       ENDOCRINE RESEARCH SOLUTIONS         -1      0       1  0  0
2   7b451cf7-5baf-4825-b63e-6aac3f1c1c1c                  2                           HENRY FORD HEALTH SYSTEM         -1      0       1  0  0
3   f61dd556-ffcd-4523-868d-7b55444b9e49                  3                HOAG MEMORIAL HOSPITAL PRESBYTERIAN         -1      0       1  0  0
4   4a8266fd-138a-48a0-9b16-4a9b9494a9f2                  4  INTERNATIONAL DIABETES CENTER - HEALTHPARTNERS...         -1      0       2  0  0
5   a13304cf-c2cb-4c81-8221-2c2f884e23ac                  5                               BARBARA DAVIS CENTER         -1      0       2  0  0
6   27a3e25b-fdb0-4176-a0c6-139faa073623                  6                            NORTHWESTERN UNIVERSITY         -1      0       1  0  0
7   780c7b0c-c278-4000-97e4-8c169fd064bd                  7                   RAINIER CLINICAL RESEARCH CENTER         -1      0       1  0  0
8   a834811e-93a0-4972-b5eb-2f389876d21f                  8                   TEXAS DIABETES AND ENDOCRINOLOGY         -1      0       2  0  0
9   a84decf0-0d65-4953-ad19-c83f2cca1b24                  9                                STANFORD UNIVERSITY         -1      0       1  0  0
10  55633dea-f0d9-4e0b-ae6f-00619e8d5ca1                 10                           UNIVERSITY OF WASHINGTON         -1      0       1  0  0
11  3ebaf5f3-b4bc-4a9a-82a7-db41278c8f70                 11              ICAHN SCHOOL OF MEDICINE AT MT. SINAI          0      0       3  0  0
12  ea30eb6d-f641-4f2c-8256-e267ed8708de                 12                                        MAYO CLINIC          1      0       5  0  0
13  5dacde3c-06d6-46b3-bf6b-eca07def3802                 13                                      ALAYNE LEHMAN         -1      0       1  0  0
14  e166e30f-179f-4820-8126-3f0f5848246b                 14                                        JOHN C REED         -1      0       1  0  0
15  462082fb-0b15-4629-87a6-cadf8151c643                 15                                      DAVIDA KRUGER         -1      0       1  0  0
16  322e4db1-96a2-4f99-9865-20911267126c                 16                                    BRITTANY DENNIS         -1      0       1  0  0
17  b586c94f-7961-4396-891a-06d01f767968                 17                                 RICHARD BERGENSTAL         -1      0       1  0  0
18  a1619c07-938f-42e6-acc6-7e1a8038d6c0                 18                                       KATHRYN LEET         -1      0       1  0  0
19  9802685c-1f4e-4a9a-80b5-36b1bc639031                 19                                     SAMANTHA LANGE         -1      0       1  0  0
20  4df76db6-aa8c-4f1b-85df-969fb44eee60                 20                                         ERIN COBRY         -1      0       1  0  0
21  730156f8-8413-4004-a20c-648304c2a899                 21                                      GRAZIA ALEPPO         -1      0       1  0  0
22  3009b0b1-a68b-40bf-bcab-92ab52e702cd                 22                                       WYATT LARSON         -1      0       1  0  0
23  58b60626-2e0f-4947-bfcf-320d03c3ff60                 23                                          JEAN CHEN         -1      0       1  0  0
24  cdba9e83-e21f-4cd6-9435-f024d9f2b576                 24                                     EMMANUEL LOPEZ         -1      0       1  0  0
25  c0143882-defe-4b18-826b-0eb5c3f2ef51                 25                                         RAYHAN LAL         -1      0       1  0  0
26  fce60c14-f276-4353-ab57-8f3aedf0b235                 26                                      DORI KHAKPOUR         -1      0       1  0  0
27  9bc66af4-b7fe-4f34-a714-8ff7002a7576                 27                                   CAMILLA LEVISTER          0      0       1  0  0
28  3b46b3e2-10ef-4c94-921b-28787de9c1bf                 28                                     DENISA TAMAREZ          0      0       1  0  0
29  19d40450-a61d-4706-b68e-498bcae6b4c1                 29                    SUNY UPSTATE MEDICAL UNIVERSITY          3      0       3  0  0
30  e2f078f5-de66-4fbc-93eb-fdbf4c82f074                 30                     MASSACHUSETTS GENERAL HOSPITAL          2      0       1  0  0
31  eac85ef3-26cc-4bc0-8c82-1d06f4f98ab3                 31                                       YOGISH KUDVA          1      0       1  0  0
32  c28c4844-34a7-43eb-87b9-7ecd5c7333a0                 32                                       SUZAN BZDICK          3      0       1  0  0
33  7c4fbd9e-fcb5-4670-abac-f6ef1218fd57                 33                                     RUTH WEINSTOCK          3      0       1  0  0
34  c0a779f2-a09a-4e28-90e5-1ccaa95ab11b                 34                                        COREY KUREK          1      0       1  0  0
35  3355e819-f328-4661-bde5-a03df2ac7e67                 35                                    TYPE 1 DIABETES          2      0       4  0  0
36  9840adef-b1ce-4aa7-b167-17c091278104                 36    OPEN, SINGLE ARM, PROSPECTIVE MULTICENTER STUDY         -1      0       1  0  0
37  35469175-eb9b-4186-930b-cafbd4efb211                 37                               CAPILLARY BIOMEDICAL         -1      0       1  0  0
38  b8d49b6e-1a86-4780-a7f1-1d86b7d68beb                 38                      TANDEM T:SLIM X2 INSULIN PUMP         -1      0       1  0  0
39  2a1ed965-11cf-4636-b270-bf9bd6c0dc2d                 39                                      UNITED STATES         -1      0       1  0  0
40  dde4249a-81ec-4b93-95a2-5b04d58d9086                 40                                   STUDY START DATE         -1      0       1  0  0
41  81f90381-bb86-4588-94c9-a4ab26b80e85                 41                              STUDY COMPLETION DATE         -1      0       1  0  0
42  cbec8a5b-fc4e-4319-b8f2-4c9525016026                 42                            INVESTIGATIONAL CENTERS         -1      0       1  0  0
43  43a42910-eb85-4e8f-99cf-d283c1d2e3eb                 43                                       PARTICIPANTS         -1      0       4  0  0
44  279dad2a-4552-4457-af5d-759a3dc7e843                 44                              CONTROL-IQ TECHNOLOGY         -1      0       1  0  0
45  64c51694-6b9e-4ddb-8451-4e76425d7033                 45                               HEALTH CARE PROVIDER         -1      0       1  0  0
⠴ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
⠧ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
🚀 create_final_text_units
                                                  id  human_readable_id  ...                                         entity_ids                                   relationship_ids
0  07f278f06b63ed15ed77a88b4e3f11e9c513e1eef938ab...                  1  ...  [fdc16e1b-7185-465a-856f-c05a85527d8e, 70b4165...  [f1e50899-600a-41e7-935d-487e92eb0876, 91eb613...
1  50fcd19011dc02899d75146662bd0110ec7409cbfdb069...                  2  ...  [fdc16e1b-7185-465a-856f-c05a85527d8e, 3ebaf5f...  [f1e50899-600a-41e7-935d-487e92eb0876, fd0ec25...
2  616a07f970269a050eb7cbc6b8cb2dc7a410cc16f686fd...                  3  ...  [3355e819-f328-4661-bde5-a03df2ac7e67, 3546917...  [9939511d-d7af-48d4-8065-294a0d4572aa, dc99257...

[3 rows x 7 columns]
⠧ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
├── extract_graph
├── compute_communities
⠏ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
├── extract_graph
├── compute_communities
├── create_final_entities
├── create_final_relationships
├── create_final_communities
├── create_final_nodes
├── create_final_text_units
/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/graphrag/index/flows/create_final_community_reports.py:172: SettingWithCopyWarning: 
A value is trying to be set on a copy of a slice from a DataFrame.
Try using .loc[row_indexer,col_indexer] = value instead

See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy
  input.loc[:, NODE_DETAILS] = input.loc[
⠏ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
├── extract_graph
├── compute_communities
├── create_final_entities
├── create_final_relationships
├── create_final_communities
├── create_final_nodes
 *************** index/graph/extractors/community_reports/community_reports_extractor.py, calling LLM
⠸ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
├── extract_graph
├── compute_communities
├── create_final_entities
├── create_final_relationships
├── create_final_communities
├── create_final_nodes
├── create_final_text_units
└── create_final_community_reports2024-12-15 21:54:21,939 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:54:21,940 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:54:21,942 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={'json': True, 'name': 'create_community_report', 'json_model': <class 'graphrag.index.graph.extractors.community_reports.community_reports_extractor.CommunityReportResponse'>, 'model_parameters': {'max_tokens': 2000}}
2024-12-15 21:54:21,942 - DataikuChatLLM - INFO - DataikuChatLLM: Response text: {
    "title": "Icahn School of Medicine and Insulin Infusion Study",
    "summary": "The community centers around the Icahn School of Medicine at Mt. Sinai, a leading institution involved in clinical research, particularly in diabetes care. Key entities include principal investigator Camilla Levister and contact person Denisa Tamarez, both of whom are associated with an insulin infusion set study, highlighting the school's engagement in diabetes-related clinical research.",
    "rating": 6.5,
    "rating_explanation": "The impact severity rating is moderately high due to the significance of diabetes research and its implications for public health.",
    "findings": [
        {
            "summary": "Importance of Icahn School of Medicine",
            "explanation": "The Icahn School of Medicine at Mt. Sinai is a pivotal entity in this community, recognized for its clinical research and education in medicine, with a focus on diabetes care. By serving as a clinical site for studies, it plays a crucial role in advancing medical knowledge and treatment options in diabetes. The school's prominence in the field suggests that its research outputs could have widespread implications for public health, especially concerning diabetes, which is a prevalent and serious condition affecting millions. This central role significantly contributes to the community's overall impact potential [Data: Entities (11), Relationships (14, 15)]."
        },
        {
            "summary": "Role of Principal Investigator Camilla Levister",
            "explanation": "Camilla Levister serves as a principal investigator at the Icahn School of Medicine, overseeing critical research initiatives such as the insulin infusion set study. Her expertise and leadership in this project are vital for ensuring the study's success. As a key figure, Levister’s contributions to diabetes research can potentially lead to breakthroughs in treatment, thereby affecting patient care outcomes significantly. The relationship between Levister and the Icahn School of Medicine underscores the importance of strong leadership in medical research and its direct impact on advancing healthcare practices [Data: Entities (27), Relationships (14)]."
        },
        {
            "summary": "Significance of Denisa Tamarez's role",
            "explanation": "Denisa Tamarez functions as a contact person for the insulin infusion set study at the Icahn School of Medicine, providing essential support to the principal investigator and facilitating communication regarding the study. While her role may appear less prominent compared to Levister, it is nonetheless critical in ensuring that the study's logistics and participant interactions are handled efficiently. Effective operational support is crucial for the success of clinical trials, and Tamarez's position may influence participant engagement and the overall study process, thereby enhancing the research's reliability and outcomes [Data: Entities (28), Relationships (15)]."
        },
 *************** index/graph/extractors/community_reports/community_reports_extractor.py, calling LLM
⠙ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
├── extract_graph
├── compute_communities
├── create_final_entities
├── create_final_relationships
├── create_final_communities
├── create_final_nodes
├── create_final_text_units
└── create_final_community_reports2024-12-15 21:54:29,317 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:54:29,317 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:54:29,317 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={'json': True, 'name': 'create_community_report', 'json_model': <class 'graphrag.index.graph.extractors.community_reports.community_reports_extractor.CommunityReportResponse'>, 'model_parameters': {'max_tokens': 2000}}
2024-12-15 21:54:29,317 - DataikuChatLLM - INFO - DataikuChatLLM: Response text: {
    "title": "Mayo Clinic Diabetes Research Community",
    "summary": "The community is centered around the Mayo Clinic, particularly focusing on diabetes research and clinical studies. Key entities include principal investigator Yogish Kudva and contact person Corey Kurek, both of whom have direct roles in managing diabetes-related studies at the clinic.",
    "rating": 7.5,
    "rating_explanation": "The impact severity rating is high due to the influential role of Mayo Clinic in advancing medical research and patient care in diabetes treatment.",
    "findings": [
        {
            "summary": "Mayo Clinic's groundbreaking role in diabetes research",
            "explanation": "Mayo Clinic is a major nonprofit medical practice and research group, well-regarded for its focus on various health conditions, especially diabetes. The clinic’s stature in the medical community highlights its importance in shaping diabetes research and patient care protocols. Their involvement in diverse clinical studies positions them as leaders in innovative treatment methodologies. [Data: Entities (12)]"
        },
        {
            "summary": "Professor Yogish Kudva's pivotal role in diabetes studies",
            "explanation": "Yogish Kudva serves as the principal investigator at Mayo Clinic for diabetes studies, making him a key figure in the research community. His direct involvement in overseeing clinical trials ensures that investigations adhere to scientific rigor, potentially leading to breakthroughs in diabetes treatment and management. Kudva's expertise enhances the credibility and effectiveness of the studies conducted under his guidance. [Data: Entities (31), Relationships (18)]"
        },
        {
            "summary": "Corey Kurek as a liaison for diabetes research",
            "explanation": "Corey Kurek functions as a contact person at Mayo Clinic for clinical trials related to diabetes, linking patients and interested parties to ongoing research initiatives. His role is significant in disseminating information about studies and increasing patient participation, which is vital for the success of clinical trials. Kurek's direct association with the organization underscores the importance of effective communication in clinical research. [Data: Entities (34), Relationships (19)]"
        },
        {
            "summary": "Current clinical studies at Mayo Clinic",
            "explanation": "Mayo Clinic is engaged in a clinical study related to diabetes, although it is not yet recruiting participants. This indicates ongoing research efforts aimed at improving treatment methods. The clinic's status as a clinical site involved in studies like the insulin infusion set could lead to new insights and innovations in diabetes management, vital for both patient care and scientific literature. [Data: Relationships (16)]"
        },
 *************** index/graph/extractors/community_reports/community_reports_extractor.py, calling LLM
⠸ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
├── extract_graph
├── compute_communities
├── create_final_entities
├── create_final_relationships
├── create_final_communities
├── create_final_nodes
├── create_final_text_units
└── create_final_community_reports2024-12-15 21:54:36,213 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:54:36,213 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:54:36,213 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={'json': True, 'name': 'create_community_report', 'json_model': <class 'graphrag.index.graph.extractors.community_reports.community_reports_extractor.CommunityReportResponse'>, 'model_parameters': {'max_tokens': 2000}}
2024-12-15 21:54:36,213 - DataikuChatLLM - INFO - DataikuChatLLM: Response text: {
    "title": "Type 1 Diabetes Research and Support Community",
    "summary": "The community focuses on Type 1 Diabetes, characterized by inadequate insulin production, and is supported by key entities like Massachusetts General Hospital and the Icahn School of Medicine at Mt. Sinai, both of which are involved in research and clinical studies related to diabetes. Their relationships highlight a collaborative effort in combating this chronic condition.",
    "rating": 7.5,
    "rating_explanation": "The impact severity rating is high due to the significant clinical focus and research efforts aimed at improving outcomes for individuals with Type 1 Diabetes.",
    "findings": [
        {
            "summary": "Type 1 Diabetes as a critical health issue",
            "explanation": "Type 1 Diabetes presents serious health challenges since it requires lifelong management and poses risks of various complications, emphasizing the need for ongoing research and clinical support. Given that this condition involves continuous insulin treatment and monitoring, the importance of dedicated healthcare systems and innovative solutions is paramount for patient care. This creates a significant need for community resources and research initiatives to develop better treatment protocols and improve patient quality of life. [Data: Entities (35), Relationships (24)]"
        },
        {
            "summary": "Massachusetts General Hospital's involvement",
            "explanation": "Massachusetts General Hospital plays a pivotal role in diabetes research and clinical trials, showcasing its commitment to addressing issues related to Type 1 Diabetes. As a renowned teaching hospital, it employs cutting-edge medical practices and contributes to clinical studies focused on the management and understanding of this disease. The hospital's research initiatives promote advancements in treatment options, which can greatly enhance the health outcomes of those affected. [Data: Entities (30), Relationships (24)]"
        },
        {
            "summary": "Icahn School of Medicine's research participation",
            "explanation": "The Icahn School of Medicine at Mt. Sinai confirms its direct involvement in clinical studies related to Type 1 Diabetes, reflecting a collaborative approach to tackling the condition. Their engagement demonstrates significant academic interest and research infrastructure aimed at exploring novel therapeutic strategies. This partnership underlines the institutional commitment to innovative research and the shared goal of improving healthcare strategies for diabetes management. [Data: Relationships (17)]"
        },
 *************** index/graph/extractors/community_reports/community_reports_extractor.py, calling LLM
⠋ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
├── extract_graph
├── compute_communities
├── create_final_entities
├── create_final_relationships
├── create_final_communities
├── create_final_nodes
├── create_final_text_units
└── create_final_community_reports2024-12-15 21:54:46,741 - DataikuChatLLM - INFO - DataikuChatLLM: Detected community-related prompt
2024-12-15 21:54:46,742 - DataikuChatLLM - INFO - DataikuChatLLM: stream=None
2024-12-15 21:54:46,742 - DataikuChatLLM - INFO - DataikuChatLLM: kwargs={'json': True, 'name': 'create_community_report', 'json_model': <class 'graphrag.index.graph.extractors.community_reports.community_reports_extractor.CommunityReportResponse'>, 'model_parameters': {'max_tokens': 2000}}
2024-12-15 21:54:46,742 - DataikuChatLLM - INFO - DataikuChatLLM: Response text: {
    "title": "SUNY Upstate Medical University and Diabetes Research",
    "summary": "The community is centered around SUNY Upstate Medical University, which specializes in health sciences and is actively engaged in diabetes research. Key entities, including contact person Suzane Bzdick and principal investigator Ruth Weinstock, are interrelated through their roles in research studies and patient recruitment.",
    "rating": 6.5,
    "rating_explanation": "The impact severity rating reflects the community's significant role in diabetes treatment research, affecting public health and policy.",
    "findings": [
        {
            "summary": "Significance of SUNY Upstate Medical University",
            "explanation": "SUNY Upstate Medical University plays a crucial role in advancing health sciences, particularly through its diabetes research initiatives. Located in Syracuse, New York, this institution not only specializes in health sciences but is also actively involved in recruiting participants for clinical studies focused on diabetes treatment. Its commitment to research has implications for public health advancements in diabetes care, which is a pressing health concern. [Data: Entities (29)]"
        },
        {
            "summary": "Role of Suzane Bzdick in diabetes studies",
            "explanation": "Suzane Bzdick serves as a registered nurse and key contact person for diabetes studies at SUNY Upstate Medical University. Her position emphasizes the importance of clinical staff in facilitating research and patient engagement. As a contact, she plays a critical role in communication and coordination between the university and potential study participants, thereby enhancing recruitment efforts. This direct involvement supports the university's research goals and increases the likelihood of successful study outcomes. [Data: Entities (32), Relationships (21)]"
        },
        {
            "summary": "Ruth Weinstock as a principal investigator",
            "explanation": "Ruth Weinstock is a principal investigator specializing in diabetes research at SUNY Upstate Medical University. Her leadership in research studies signifies the institution's focus on cutting-edge diabetes treatment methodologies. As a principal investigator, Weinstock is responsible for overseeing research protocols, ensuring compliance with regulatory standards, and leading scientific inquiry that can significantly influence diabetes management practices. Her work contributes to the broader understanding of diabetes, potentially leading to advancements in treatment and patient care. [Data: Entities (33), Relationships (22)]"
        },
        {
            "summary": "Interconnection between key entities",
            "explanation": "The relationships between SUNY Upstate Medical University, Suzane Bzdick, and Ruth Weinstock showcase a structured collaboration focused on diabetes studies. Bzdick's role as a contact person and Weinstock's stature as a principal investigator demonstrate an integrated approach to clinical research, enhancing the university's capability to conduct significant studies. This interconnectedness allows for smooth operations in patient recruitment and research implementation, fostering a supportive environment for advancing diabetes treatments. [Data: Relationships (21, 22)]"
        },
⠴ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
├── extract_graph
├── compute_communities
├── create_final_entities
├── create_final_relationships
├── create_final_communities
├── create_final_nodes
├── create_final_text_units
└── create_final_community_reports2024-12-15 21:54:46,752 - create_final_community_reports - DEBUG - After summarize_communities: columns=[] shape=(0, 0)
2024-12-15 21:54:46,752 - create_final_community_reports - DEBUG - community_reports head:
Empty DataFrame
Columns: []
Index: []
2024-12-15 21:54:46,752 - create_final_community_reports - DEBUG - Error: 'community' column not found in community_reports. Columns: []
2024-12-15 21:54:46,753 - datashaper.workflow.workflow - ERROR - Error executing verb "create_final_community_reports" in create_final_community_reports: 'community'
Traceback (most recent call last):
ERROR: Error executing verb "create_final_community_reports" in create_final_community_reports: 'community'
Exception: 'community'
Stack Trace: Traceback (most recent call last):
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/datashaper/workflow/workflow.py", line 415, in _execute_verb
    result = await result
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/graphrag/index/workflows/v1/create_final_community_reports.py", line 89, in workflow
    output = await create_final_community_reports(
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/graphrag/index/flows/create_final_community_reports.py", line 124, in create_final_community_reports
    community_reports["community"] = community_reports["community"].astype(int)
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/pandas/core/frame.py", line 4102, in __getitem__
    indexer = self.columns.get_loc(key)
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/pandas/core/indexes/range.py", line 417, in get_loc
    raise KeyError(key)
KeyError: 'community'

⠦ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
├── extract_graph
├── compute_communities
├── create_final_entities
├── create_final_relationships
├── create_final_communities
├── create_final_nodes
├── create_final_text_units
└── create_final_community_reports2024-12-15 21:54:46,775 - graphrag.callbacks.file_workflow_callbacks - INFO - Error executing verb "create_final_community_reports" in create_final_community_reports: 'community' details=None
2024-12-15 21:54:46,775 - graphrag.index.run.run - ERROR - error running workflow create_final_community_reports
Traceback (most recent call last):
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/graphrag/index/run/run.py", line 262, in run_pipeline
    result = await _process_workflow(
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/graphrag/index/run/workflow.py", line 103, in _process_workflow
    result = await workflow.run(context, callbacks)
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/datashaper/workflow/workflow.py", line 369, in run
    timing = await self._execute_verb(node, context, callbacks)
Traceback (most recent call last):
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/graphrag/index/run/run.py", line 262, in run_pipeline
    result = await _process_workflow(
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/graphrag/index/run/workflow.py", line 103, in _process_workflow
    result = await workflow.run(context, callbacks)
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/datashaper/workflow/workflow.py", line 369, in run
    timing = await self._execute_verb(node, context, callbacks)
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/datashaper/workflow/workflow.py", line 415, in _execute_verb
    result = await result
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/graphrag/index/workflows/v1/create_final_community_reports.py", line 89, in workflow
    output = await create_final_community_reports(
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/graphrag/index/flows/create_final_community_reports.py", line 124, in create_final_community_reports
    community_reports["community"] = community_reports["community"].astype(int)
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/pandas/core/frame.py", line 4102, in __getitem__
    indexer = self.columns.get_loc(key)
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/pandas/core/indexes/range.py", line 417, in get_loc
    raise KeyError(key)
KeyError: 'community'

During handling of the above exception, another exception occurred:

Traceback (most recent call last):
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/plugins/dev/graphrag/python-lib/graphrag/test/test.py", line 106, in <module>
    asyncio.run(main())
  File "/opt/homebrew/Cellar/python@3.10/3.10.12_1/Frameworks/Python.framework/Versions/3.10/lib/python3.10/asyncio/runners.py", line 44, in run
    return loop.run_until_complete(main)
  File "/opt/homebrew/Cellar/python@3.10/3.10.12_1/Frameworks/Python.framework/Versions/3.10/lib/python3.10/asyncio/base_events.py", line 649, in run_until_complete
    return future.result()
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/plugins/dev/graphrag/python-lib/graphrag/test/test.py", line 86, in main
    outputs = await build_index(
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/graphrag/api/index.py", line 68, in build_index
    async for output in run_pipeline_with_config(
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/graphrag/index/run/run.py", line 174, in run_pipeline_with_config
    async for table in run_pipeline(
  File "/Users/abdelmajidboubrik/Library/DataScienceStudio/dss_home/code-envs/python/graphrag/lib/python3.10/site-packages/graphrag/index/run/run.py", line 279, in run_pipeline
    cast("WorkflowCallbacks", callbacks).on_error(
AttributeError: 'list' object has no attribute 'on_error'
⠦ GraphRAG Indexer 
├── Loading Input (text) - 1 files loaded (0 filtered) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 100% 0:00:00 0:00:00
├── create_base_text_units
├── create_final_documents
├── extract_graph
├── compute_communities
├── create_final_entities
├── create_final_relationships
├── create_final_communities
├── create_final_nodes
├── create_final_text_units
└── create_final_community_reports%                                                                                                                                                                                                          (graphrag) abdelmajidboubrik@fr-mac-aboubrik test % 
